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ABSTRACT

BACKGROUND: Peripheral artery disease (PAD) is a major cause of morbidity and
mortality that arises from atherosclerotic vascular disease. Severe PAD, or critical limb
ischemia (CLI) in the extremities can lead to recurrent pain, non-healing ulcers, gangrene,
and

often

requires

amputation.

Unfortunately,

surgical

and

percutaneous

revascularization strategies for CLI are often unsuccessful. A major reason for disease
recurrence and treatment failure is likely co-existing abnormalities in the distal
microvasculature. However, these small vessels are not seen clinically and there is little
known about their structure and function in patients with PAD. The status of the
microcirculation in ischemic muscle could be critical to informing strategies for modulating
and potentially normalizing the distal vasculature in PAD.
The purpose of this study was to delineate abnormalities in the
microvascular wall in the ischemic skeletal muscle of patients with CLI.

METHODS: To elucidate the microvascular landscape in CLI, we studied human tibialis
anterior (TA, n=14) and gastrocnemius (n=10) muscles harvested from below-knee or
above knew leg amputations of 10 individuals with CLI. Control muscles, from individuals
without PAD, were obtained from TA (n=2) and vastus lateralis (n=4) samples. Formalin
fixed, paraffin-embedded muscle sections were stained with hematoxylin and eosin,
Mason’s trichrome and immunostained for endothelial cell maker, CD31, the
mesenchymal cell markers, N-Cadherin, smooth muscle-a-actin, S100A4, and Snail, and
the signaling molecules pSMAD2/3, TGFß1, and Endgolin.

RESULTS: CLI but not Non-PAD samples had myofiber damage features. Capillary
density, quantified from CD31-stained sections, was 1.8-fold higher in CLI skeletal muscle
(*p=0.009). Furthermore, the density of small arterioles (8 - 40 µm diameter) was also
significantly increased in CLI samples (*p=0.0002). Surprisingly, the arterioles in subjects
with CLI, particularly those 8 - 20 µm in diameter, were found to be stenotic, with at least
a 40% reduction in lumen area. Moreover, the area of the endothelium was 1.2-fold
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greater (*p<0.0001) in arterioles of CLI patients. The endothelial cells themselves
underwent a reorientation and were rounded, causing them to obstruct the lumen
(*p<0.0001). Notably, 9% of the small arterioles in CLI patients were completely occluded,
while an additional 33% were stenotic.
These aberrant endothelial cells showed a striking shift in N-cadherin localization,
from diffuse staining to junctional and apical enrichment, in addition to overall
upregulation within the small arterioles of CLI patients (*p=0.0007). Furthermore, the
obstructive endothelial cells expressed CD31 along with mesenchymal cell markers
S100A4 and Snail, indicating partial endothelial to mesenchymal transition (EndMT). To
determine the mechanism of activation for the partial EndMT. Immunostaining for
activated, pSMAD2/3 revealed a 1.4-fold higher signal in endothelial cells of CLI arterioles
(*p=0.0078). As well, the mural cells of CLI arterioles had a 63-fold higher expression of
TGFß1 than control arterioles, together implicating TGFß signaling in driving the EndMT
process in CLI arterioles.

CONCLUSIONS: Skeletal muscles of patients with critical PAD demonstrated endothelial
cell-based arteriolar stenosis, a previously unidentified phenomenon. The bulky and
reoriented endothelial cells expressed mesenchymal markers and had evidence for
augmented TGFß signaling. The findings suggest a newly recognized structural basis for
impeding blood flow to the muscles and may, in part, explain the limited success of
revascularization procedures.

Keywords: endothelial to mesenchymal transition, arterioles, microvasculature, critical
limb ischemia, skeletal muscle, endothelial cell, N-cadherin, TGFß
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SUMMARY FOR LAY AUDIENCE
The muscles that exist in our legs require a tremendous amount of blood to keep
healthy. In some individuals, the blood supply to the legs is impaired because of plaque
build-up in the arteries that deliver the blood to the legs. When severe, this can result in
severe leg pain, skin ulcers that don’t heal, and ultimately, it may require the leg to be
amputated. Diabetics are especially prone to this serious problem.
The main treatment for severe blood vessel disease in the legs is surgical bypass
or stenting. However, these procedures are not effective for many individuals and an
amputation is still necessary. This is a major and world-wide problem.
One reason surgery is ineffective for so many individuals is that not only is there
plaque build-up in the leg arteries, but there is also narrowing of the tiny blood vessels –
called arterioles – that dive into the muscles themselves. However, because these
vessels are so small, they are exceedingly difficult to study.
In this thesis, I have established that in legs that have sufficiently poor blood flow
that an amputation is necessary, there is a serious problem with the small arterioles. I
examined tissue from these legs using highly sophisticated microscopy techniques. I
discovered that the inner lining of arterioles is no longer thin and smooth. Instead, the
cells that make up the inner lining, called endothelial cells, become so bulky that they clog
the small channels, preventing the blood from flowing. I also discovered that these
endothelial cells actually convert into a different type of cell that has a tendency to stick
to its nearby neighbours, a bad situation for blood vessels.
These discoveries could explain why bypass procedures fail in many people,
because the small clogged arterioles cannot be bypassed. The findings could also open
possibilities for new strategies to improve the blood flow in individuals with narrowing of
the leg arteries.
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CHAPTER 1:

GENERAL INTRODUCTION
Peripheral artery disease (PAD) is a major cause of morbidity and mortality in
North America.1 It is a disease that arises from atherosclerosis in arteries other than those
that supply the heart and brain. Severe PAD in the extremities can lead to recurrent pain,
non-healing ulcers, gangrene, and often requires amputation.1 Unfortunately, surgical and
percutaneous revascularization strategies for PAD are often unsuccessful. A major
reason for disease recurrence and treatment failure is likely co-existing abnormalities in
the distal microvasculature.2 However, these small, distal vessels are not assessed
clinically and there is little known about their structure and function in patients with PAD.
Recently, our research group has discovered several unexpected microstructural
and network abnormalities that develop in the hindlimb microcirculation of mice following
severe ischemic injury.3 However, the nature of and extent to which skeletal muscle
microvascular restructuring proceeds in humans with chronic severe PAD is unknown.
This could be critical to informing strategies for modulating and potentially normalizing the
distal vasculature in PAD. Accordingly, the overarching purpose of my thesis was to
elucidate microvascular abnormalities in skeletal muscle of patients suffering from severe
peripheral artery disease.

My specific objective was:
To delineate abnormalities in the wall of microvessels in critically ischemic skeletal
muscle, with a focus on endothelial cell phenotypes.

1.1

Peripheral Artery Disease
Peripheral artery disease (PAD) is caused by accumulation of atherosclerotic plaque

in the arteries that supply organs other than the heart and brain, with the lower legs being
the most commonly affected (Figure 1.1).1 PAD is often diagnosed by a reduction of the
ankle-brachial index, which is the ratio of the highest blood pressure in the posterior tibial

2

Figure 1.1 Schematic Representation of Peripheral Artery Disease

Peripheral artery disease is a consequence of atherosclerotic plaque build-up in large
and medium size arteries which limits blood supply primarily to the lower limbs. Clinically,
the small vessels cannot be visualized, limiting treatment to the larger vessels.

Case courtesy of Dr David Cuete, Radiopaedia.org, rID: 25682
https://radiopaedia.org/articles/peripheral-arterial-disease

3

4
artery to the highest blood pressure in the brachial artery.1 Cardiovascular risk factors for
PAD include smoking, diabetes, hypertension, and dyslipidemia; but in particular smoking
and diabetes are associated with worse outcomes, independent of other risk factors.4–6
PAD can affect the leg both at rest and during exercise, and its progression leads to one
of two clinical manifestations: intermittent claudication and critical limb ischemia (CLI).1,4
Intermittent claudication is characterized as calf or buttock pain during exercise and is
relieved by rest. By contrast, CLI results in extreme pain even while at rest. Consistent
with this continuous ischemia, CLI is often associated with ulcers or gangrene. In the
absence of successful revascularization, 20% to 40% of patients will require amputation,
resulting in poor quality of life, contributing to long-term disability and severe functional
impairment, which leads to significant costs in health care.4,5,7,8
The goals of treatment for patients with intermittent claudication are to relieve the
symptoms, improve walking capacity, and improve quality of life. In cases of CLI, along
with these goals, there is the additional intent to relieve ischemic pain at rest, heal
ulceration, and prevent limb loss.9 In the early stages of PAD, medical professionals
encourage risk factor reduction and lifestyle modification, including exercise rehabilitation
and ceasing smoking. The use of antiplatelet drugs and Angiotensin-Converting-Enzyme
(ACE) inhibitors to reduce cardiovascular risk are also commonly used. Additionally,
recent trials of direct oral anticoagulants have shown promise.10
CLI is typically an end-stage presentation of PAD and is currently treated via
surgical and endovascular revascularization procedures, with surgical bypass remaining
the gold standard for revascularization for these patients. However, many of the patients
suffering from CLI are poor candidates for revascularization procedures, and for the few
that are eligible, there is a high rate of reoccurrence.4,7 For those that are fortunate
enough to undergo a revascularization procedure, whether it is surgical bypass or
endovascular therapies, about 25 – 66 % will fail to survive with an intact limb at 1 year.11
A major reason for disease recurrence and treatment failure is believed to be co-existing
abnormalities in the distal microvasculature.2 However, these small vessels are not
visualized with the standard clinical angiography techniques. In fact, little is known about
their structure and function in patients with PAD.
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1.2

Skeletal Muscle
The skeletal muscle of the leg is the primary organ affected by CLI.1 The skeletal

muscle is a metabolically active tissue which allows it to generate longitudinal contraction.
As such, it requires a large amount of blood flow during both rest and exercise to support
its metabolic activity, making it very vulnerable in patients with PAD.
Skeletal muscles consists of bundles of parallel and dense muscle fiber, which are
comprised of multinucleated cells derived from myoblasts.12,13 The myofibers are closely
packed together and surrounded by the endomysium. Groups of myofibers will be
wrapped into bundles called fascicles surrounded by perimysium, which will then be
bundled to create a whole muscle. This highly organized, highly cellular tissue generates
longitudinal contraction because of the strict cellular orientation.12,13
In normal muscle repair following acute injury, damaged or dead myofibers will be
digested and removed by macrophages.12–14 Satellite cells, a specialized stem cell subpopulation, initiate regeneration in response to specific local factors. They begin to
proliferate and will differentiate into myoblasts which then fuse to form the multinucleated
and elongated myotubes which combine to form muscle fibers. The basal lamina can
serve as a scaffold for the reconstruction of the regenerating muscle fibers. By contrast,
if the injured area has had disruption of the basal lamina by fibrosis, then the complete
regeneration of muscle fibers may be inhibited.12–14 Myofiber regeneration plays an
important role in the skeletal muscle recovery from ischemic injury (See Section 1.4.1
Muscle Histopathology in CLI).

1.3

The Skeletal Muscle Circulation
The microcirculation contains the smallest blood vessels within the cardiovascular

system, ranging from 5 µm to ~150-200 µm in diameter.15 The microvasculature is
responsible for delivering oxygen and nutrients to all cells within the body, including the
skeletal muscle.16 It is a tightly regulated system which precisely controls the amount of
oxygen-rich blood sent to areas within an organ in order to meet the metabolic demands
of the tissue with the goal of maintaining homeostasis.16 Key aspects of the
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microvasculature which allow it to function effectively include: the architecture, the
hierarchy, and the cellular structure of the microvessels.

1.3.1 Microcirculation Architecture and Hierarchy
The basic unit of blood flow control is the microvascular unit (Figure 1.2), which is
comprised of an arteriole, terminal arteriole (pre-capillary arteriole), capillary network,
post-capillary venule, and venule.3 The arterioles and terminal arterioles regulate the flow
of oxygen-rich blood into downstream capillaries by dilation and constriction in response
to the metabolic demand of the tissue.17 The capillaries supply oxygen by passive
diffusion to the surrounding tissue.18 Following oxygen exchange to the tissue, the
capillary network will drain into post-capillary venules, which will feed into the venous
return system.
In the skeletal muscle, arteries symmetrically bifurcate and branch into arterioles
and terminal arterioles which run in an orthogonal orientation to the muscle fibers. The
terminal arterioles then branch into capillary networks which run parallel to and between
the muscle fiber. Skeletal muscle capillaries are 4-8 µm in diameter19 and approximately
0.5-1 mm in length.20 The red blood cells (RBC) are approximately 4-8 µm in diameter
and therefore travel in single file in a normal capillary. Given that RBCs transiting in
capillaries provide oxygen to the surrounding tissue by passive diffusion, there is a limited
volume of tissue which each capillary can feed. It is therefore necessary for anastomoses
in capillary networks to sufficiently supply oxygen to the tissue. Additionally, the capillaries
are embedded within sarcolemmal depressions in order to maximize the contact surface
area between myocytes and the capillaries.21 The mitochondria line these grooves in
order to minimize the diffusion distance for the oxygen to reach them.21 The post-capillary
venules are located between two terminal arterioles and collect the deoxygenated blood
from the capillary beds. Ultimately, the blood drains into the larger veins which are found
deeper within the muscle.
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Figure 1.2 The Microvascular Unit in Skeletal Muscle

The basic unit of tissue blood flow is the microvascular unit. In the skeletal muscle,
arteries symmetrically bifurcate and branch into arterioles and terminal arterioles. The
latter ran orthogonal to the muscle fibers. The terminal arterioles branch into capillary
beds and capillaries which run parallel and between the muscle fibers. Capillaries are
embedded within grooves in the muscle fibers, and the myocyte mitochondria are closely
opposed to these grooves in order to maximize the contact surface area between
myocytes and the capillaries and minimize the diffusion distance for oxygen.
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1.3.2 Microcirculation Cellular Structure
Each order of microvessels in the microcirculation has a specific and critical cellular
structure that allow them to achieve the unique roles within the microvascular unit (Figure
1.3). Below are the key cell types that make up this structure.
1.3.2.1 Endothelial Cells
All the vessels of the circulatory system are channels lined with a single layer of
endothelial cells (EC). The endothelium acts as a semi-permeable barrier which controls
the transfer of small and large molecules from the vessels to surrounding tissues.22
Healthy endothelial cells are vital for the maintenance of vascular homeostasis.
Endothelial cells are responsible for modulating vascular tone, controlling vessel
permeability, and controlling immune responses by regulating the adherence of platelets,
and leukocytes to the inner vessel wall. The properties of healthy endothelial cells
contribute to the maintenance of normal blood fluidity by their anticoagulant and
antiplatelet effects .23
There are numerous examples of how the microenvironment can regulate the
endothelial cell phenotype. Recent studies have shown that endothelial cells may be
derived from different local progenitor cells depending on the organ or tissues in which
they are found. Endothelial cell differences have been found between arteries and veins,
large and small vessels, and different microvascular beds in various organs and tissues.
Some organ-specific endothelial cell properties include vessel barrier functions,
angiogenic potential, and metabolic functions.24 To add to the complexity of organ and
vessel-specific endothelial cells, there are also multiple subpopulations of endothelial
cells being found, such as tip and stalk cells.25
A distinct but related process is endothelial cell plasticity and transdifferentiation
(see section 1.5.2 Endothelial to Mesenchymal Transition). Endothelial cells have the
innate ability to sense and respond to environmental factors by changing their phenotype.
This phenotypic plasticity reflects endothelial cell exposure to growth factors, cytokines,
oxygen and mechanical stresses, among other conditions. Accordingly, maintenance of

10

Figure 1.3 The Cellular Structure of the Microvasculature

All the arterioles and capillaries that are part of the microcirculation are made up of
endothelial cell-lined channels which are surrounded by mural cells. The pericyte is the
predominant mural cell for capillaries. In contrast, the arterioles will be circumferentially
wrapped by vascular smooth muscle cells, which constrict and relax to maintain vascular
homeostasis.
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the endothelial cell quiescent state is an active process. Key proteins such as vascular
endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1
(FGFR1) play important roles in maintaining endothelial cell homeostasis.26

1.3.2.2 Mural Cells
In addition to the endothelial layer, all orders of blood vessels have various supporting
or mural cells, which is a key point of distinction between different orders of microvessels.
Pericytes are a type of mural cell that surround the capillaries, which are the smallest of
the microvessels. In contrast to the capillaries, the contractile vascular smooth muscle
cells (SMC) contribute to the vascular wall of larger vessels, arterioles and venules.27,28
SMCs and pericytes can share many cellular markers and in some cases are best
distinguished by their morphology and location within the vasculature.29
The current accepted definition of a mature pericyte is a cell that is embedded within
the endothelial basement membrane.29 Pericytes can be mistaken for other peri-vascular
cells such as SMCs, fibroblasts, macrophages and epithelial cells, which are not located
within the basement membrane of the endothelial cells. A key morphological marker for
pericytes is the presence of primary cytoplasmic processes extending along the surface
of the endothelial tubes with secondary processes that attach to the endothelium.

30

Pericytes often span across more than one endothelial cell, yet, in the skeletal muscle,
many endothelial cells are without pericyte contact.30
By contrast, SMCs circumferentially wrap the larger microvessels and are contractile,
with expression of smooth muscle-α-actin and other contractile proteins to allow
constriction and relaxation.3 A single SMC layer surrounds the small arterioles and
terminal arterioles. Arteriole SMCs have a long, spindle-shaped appearance with few
cytoplasmic processes, whereas around the pre-capillary (terminal) arterioles, the SMC
bodies are distinctly bulky and extend several processes encircling the endothelium.30 By
contrast, on the other end of the capillary bed, SMCs on the post-capillary venules have
a compressed cell body with many slender, branching processes. SMCs on venules have
large, stellate shaped bodies with many branching processes which do not wrap
circumferentially.30
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The cellular architecture of the varying vessels reflects their specific roles within the
microcirculation. Whereas the arterioles require a circumferential wrapping to allow for
effective blood flow control by uniform constriction and relaxation of the whole vessel, the
capillaries require only supporting mural cells with little contractile properties. The venules
require the support and stability of the SMC without the need for circumferential wrapping
required for contractile function in arterioles.

1.3.3 Functional Interplay Between Endothelial Cells and Mural Cells
The interactions between endothelial cells and mural cells play a key role in biological
processes such as angiogenesis and arteriogenesis. While evaluating the endothelialpericyte interactions, studies highlight that impairment of one of the vessel wall cell types
will impact the other.31 In addition to impacting one another in pathological processes, the
relationship between endothelial cells and mural cells plays a key role in vascular
development and homeostasis.

1.3.3.1 Angiogenesis
Angiogenesis is the process by which new blood vessels develop from a preexisting vasculature.32 Over time, this network remodels into a differentiated network of
arteries, capillaries, and veins. Angiogenesis most often occurs by a process termed
sprouting angiogenesis, the goal of which is to generate new microvessels and capillaries
in tissue regions with insufficient blood flow.32
Sprouting angiogenesis occurs by activation of endothelial cells from a basal
quiescent state with the breakdown of endothelial cell junctions and increase of vessel
permeability. These changes allow the migration of an endothelial cell tip cell toward a
gradient of angiogenic factors that are produced in hypoxic tissues. The tip cells signal to
their neighboring stalk cells to proliferate and extend the length of the sprout while
suppressing migratory behaviour, as well as generating basement membrane
components and establishing junctions with neighboring endothelial cells. Following
sprout formation, the lumenization of the vessel will ensue.33,34

14
Although the endothelium has received the majority of study in regard to
angiogenesis, mural cells are recognized to be necessary to stabilize nascent vessels by
inhibiting endothelial proliferation and migration, and by stimulating production of
extracellular matrix.32 During angiogenesis, the endothelial cells will release plateletderived growth factor-B (PDGF-B) for paracrine signaling through PDGF receptor-b
(PDGFRb) on pericytes stimulating their proliferation and recruitment along the sprouts.
Pericyte recruitment at this stage plays a crucial role in vascular stability, without which
there are leaky vessels and loss of capillary diameter control.35 Angiopoietin-Tie ligandreceptors are similarly important for endothelial-mural cell association, but they work
through an inversed loop, from mural cells to the endothelium. Ang-1 is predominantly
expressed by mural and other perivascular cells, while Tie2 is expressed in the
endothelium. Studies have suggested that Tie2 and Ang-1 play important roles in
angiogenic sprouting and vascular remodeling, as well as association between
endothelial and surrounding mesenchymal cells and matrix.36 Although this is an overview
of the signaling involved in angiogenesis and mural cell recruitment, the paracrine
signaling pathways described highlight the critical role of endothelial-mural cell interplay
in angiogenesis and vascular stability.
Endothelial cells and mural cells can also respond to each other as secondary
consequences of upstream signaling, in addition to paracrine signaling. For example,
sphingosine-1-phosphate (S1P) is necessary for vascular maturation and is in high
concentration within the plasma and serum.37 S1P activates a family of G protein-coupled
receptors (S1P1 to 5) in the endothelium. S1P1 plays a role in vascular endothelial cadherin
(VE-cadherin) assembly into adherens junctions and is critical for endothelial cell
morphogenesis into capillary-like structures in vitro. Notably, N-cadherin, a cell adhesion
molecule which connects endothelial cells to mural cells, has been shown to be activated
and subsequently relocated to basal plasma membrane domains via S1P/S1P1 signaling.
S1P is critical for proper trafficking of N-cadherin to cell adhesions between endothelial
and mural cells. It has been suggested that clustering and activation of local N-cadherin
on the basal endothelial cell surface by S1P1 may induce clustering of N-cadherin on the
neighboring mural cells.36–38
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Similarly, TGFb signaling plays a role in both endothelial cells and mural cells. It
has been shown that if TGFb signaling in endothelial cells is impaired, the adjacent
mesenchymal cells showed impaired TGFb/ALK5 signaling, inhibiting their differentiation
into vascular SMCs and their association with the endothelium.31 Specifically, TGFb
signaling in endothelial cells promotes TGFb expression, synthesis, and release by these
cells, which induces differentiation of vascular SMC from surrounding mesenchymal cells.
The process also reinforces TGFb expression in the endothelial cells in an autoregulatory
loop.31 In contrast, the role of mural cell-derived TGFb during angiogenic remodelling
remains largely uncharacterized.

1.3.3.2 Arteriogenesis and Collateralization
While angiogenesis is necessary for delivery of blood and oxygen to ischemic and
regenerating tissues, arteriogenesis plays a major role in increasing bulk blood flow and
volume to the microvessels. Arteriogenesis is a process by which pre-existing collateral
arteries will enlarge into larger diameter conductance vessels.32 This remodeling
response is primarily driven by increased fluid shear stress, typically caused by the
occlusion of major arteries and diversion of flow into collateral vessels, for example in
PAD. It is characterized by the proliferation of endothelial cells and SMCs and a process
of luminal expansion and vessel wall thickening to support an increased blood flow and
shear stress.33,34

1.4

Critical Limb Ischemia
Despite the decrease in arterial flow caused by atherosclerotic build-up in the feeding

arteries, the basis for the impaired functional capacity of patients with PAD remains
controversial. In particular, altered hemodynamics does not entirely explain the degree of
functional limitations in patients with PAD.39,40 Furthermore, studies have not evaluated
the structural features of the microcirculation in the skeletal muscle from patients with CLI.
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1.4.1 Muscle Histopathology in CLI
Muscle regeneration following injury is crucial for organism survival. This process
occurs by the successful completion of a series of events that, if disrupted, can result in
persistent degeneration of myofibers, inflammation, and fibrosis.41 Muscle regeneration
occurs by the following process:
1) Injured skeletal muscle, injured blood vessels, and infiltrating inflammatory cells
will release cytokines and growth factors, which stimulate the migration of the
inflammatory cells to the site of injury.
2) Invading inflammatory cells are responsible for phagocytosing cellular debris from
the injury.
3) Satellite cells then begin their role in the formation of new muscle fibers by their
activation, followed by proliferation, and finally differentiation.
4) The differentiated myoblasts fuse to each other to form de novo fibers, or to the
damaged myofibers to replace lost muscle. Often, the satellite cells will use the
basement membranes of pre-existing necrotic fibers to ensure the myofiber
maintains a similar position.
5) The migration and proliferation of fibroblasts will help produce new temporary
extracellular matrix components which assist in stabilizing the tissue, and act as
scaffolds for the new fibers.12–14,42
This innate mechanism for muscle regeneration can be altered by chronic ischemia.
For example, chronic ischemia can induce the proliferation of satellite cells but inhibit their
differentiation, resulting in limited repair of the skeletal muscle.14,43 Consistent with the
limited repair of muscle in PAD, several laboratories have demonstrated that there is
additional myopathy present in the leg of patients with PAD. These abnormalities include
myofiber degeneration with alterations of the size and shape of myofibers, internal nuclei,
vacuolization, shift of myofiber type toward type I fibers, myofiber necrosis (Zenker’s
degeneration, discoid necrosis), fatty infiltration, and endomysial and perimysial
fibrosis.12,13,43–49
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1.4.2 Microvascular Pathology in PAD
Little is known about the state of the microvasculature in patients with CLI.
However, there is evidence that the condition of the microcirculation could determine the
outcome of revascularization procedures.50 Recently, studies have begun to characterize
the microvasculature of patients with PAD.
Studies have evaluated the capillary density in patients with PAD to determine the
extent of angiogenesis in the ischemic limb. Some studies have indicated that humans
have angiogenic capabilities, showing an increase in the capillary and microvascular
density in patients with PAD. 51–55 Others have found no significant change, or decrease
in capillary density in patients with PAD. 40,56–59
Additionally, it has been shown that the capillaries in patients with PAD have a
thickened basement membrane. This thickened layer of the basement membrane
contains more SM-a-actin positive cells, although it is uncertain whether these cells are
pericytes, fibroblasts, or SMC. It was further suggested that the capillaries in the skeletal
muscle of patients with PAD might be converted to arterioles, as has been shown in the
rats in response to increased blood flow, stretch and muscle activity.60
At the level of the small arteries (<500µm) in the subcutaneous fat and skeletal
muscle vascular beds of patients with CLI, it was shown that there is a reduction in the
media to lumen ratio due to SMC remodelling of the vessels.2,61 This remodelling inhibited
the ability of the atrophied vessels in the ischemic vascular bed to vasodilate. It was also
shown that the arterioles in the subcutaneous tissue showed an opposite effect with an
impaired vasoconstriction response. This contrast could lead to blood being diverged from
the muscle to the skin and could be the basis of a redistribution phenomenon.61
Finally, studies have evaluated the endothelium’s impaired nitric oxide signaling,
decreased nitric oxide dependent reactivity, excessive inflammation, and a delayed or
diminished response to angiogenic factors in patients with PAD.50,60–67 However, it
remains elusive how the phenotype of microvascular endothelial cells contributes to the
exacerbation of muscle ischemia and damage in the context of CLI.
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1.4.3 Ischemic Mouse Model
Inducing ischemia in the hindlimb of mice constitutes a useful model to study PAD.
Femoral artery ligation or excision provides a simple model with ease of access and a
low mortality rate.68 A recent study by Arpino et al. in the ischemic mouse model has
shown that following severe ischemic insult the regenerated microvasculature contains
abnormalities and flaws.3
Compared to the mouse model, human disease is more complex with many
confounding factors that could impact the microvasculature. These factors include:
metabolic stress from aging, disease progression over decades rather than an acute
injury, and poorer native regenerative ability of the microvasculature in humans compared
to that found in the mouse. It is acknowledged that in both small and large animal models
of PAD, the rapid collateralization that is not seen in patients diminishes the time of
ischemia. Also many models rely on induced injury which can contaminate the tissue with
physical injury.69 It is therefore crucial to evaluate the structure and functional attributes
of the microvasculature of human skeletal muscle in CLI.
1.5

Cellular Plasticity
The vascular wall is known to play a central role in maintaining homeostasis of the

cardiovascular system. Endothelial cells and mural cells show a wide range of plasticity
and differentiation potential. These processes present new opportunities to understand
organ maintenance, and new methods to moderate disease progression, improve
vascular repair, and promote regeneration.
1.5.1 Mural Cell Plasticity: Pericytes and vascular smooth muscle cells
Research in pericyte plasticity and identification is a quickly evolving field. The
accepted definition of a mature pericyte is a cell embedded within the vascular basement
membrane.30 N-cadherin is distributed in a potted fashion along the endothelium-pericyte
interface, a pattern that is disrupted when pericytes are absent.29 Pericytes are found in
capillaries, post capillary venules, and terminal arterioles. As SMCs and pericytes belong
to the mesenchymal cell lineage, they can be difficult to distinguish. There is currently no
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known single molecular marker that can be used to unequivocally identify pericytes and
distinguish them from SMC or other mesenchymal cells. This creates a limitation in
defining any microvascular periendothelial mesenchymal cell without investigating
whether they share a basement membrane. When an ultrastructural analysis is
impractical, pericytes are usually defined using a mixture of criteria including location,
morphology, and gene/protein expression.29,30,70
Pericyte morphology is described as having a cellular body that extends primary
cytoplasmic processes along the abluminal surface of the endothelial tube

30,71.

These

processes usually span several endothelial cells in human skeletal muscle. Thin
secondary processes extend perpendicularly from the primary processes, encircling the
vessel. In terms of gene and protein expression, validated markers include plateletderived growth factor receptor-beta (PDGFRb), chondroitin sulfate proteoglycan 4 (NG2),
alanyl aminopeptidase (CD13) and desmin.
Mural cell plasticity is still largely unclear because we do not know the extent that
new pericytes develop by division of pre-existing pericytes, by recruitment from preexisting SMCs on neighboring large vessels, or by transdifferentiation of other
mesenchymal cells. The continuum of mural cell phenotype observed along terminal
arterioles, capillaries, and post-capillary venules could suggest that these cells can
differentiate into each other in conjunction with vessel growth and remodeling.30,71
Intracellular signaling between the endothelial cells and the mural cells help to
maintain vascular homeostasis. As noted above, pathways such as PDGF-B, TGFb and
angiopoietin play significant roles in vascular development and stability. In particular
TGFb upregulation has been shown to lead to the activation of receptor Alk-5 in
mesenchymal cells which consequently phosphorylates SMAD2/3 and thereby promotes
mitotic and migratory quiescence and differentiation into SMC. By contrast, activation of
Alk-1 leads to phosphorylation of SMAD1/5 which promotes cell proliferation and
migration but opposes SMC differentiation. SM-a-actin has been shown to be expressed
by some pericytes and may have a contractile role in the retina and nervous system.72
Additionally, SM-a-actin is upregulated in pathological processes such as tumor

20
angiogenesis, tissue fibrosis, and inflammation. TGFb, which has been involved in SMC
maturation is a potential driver of the expression of SM-a-actin in tumour pericytes.30,31,72

1.5.2 Endothelial Cell Plasticity: Endothelial to Mesenchymal Transition
Epithelial-mesenchymal transition (EMT) is an important developmental process
which has been extensively studied in pathologies such as tumour growth.73 Recently,
endothelial-mesenchymal transition (EndMT), a newly recognized type of cellular
transdifferentiation, has been demonstrated to have an important role during embryo
development. This has been well-described in regard to valve progenitor cells and cardiac
development.26,74 EndMT is a process by which the endothelial cells will partially lose at
least some of their endothelial cell phenotype by delaminating and invading into
underlying tissues. The cells will lose endothelial cell markers such as VE-cadherin,
CD31, p100-catenin, isolectin-B4 (Figure 1.4).26,73,75 Simultaneously, the cells acquire a
mesenchymal phenotype, characterized by a loss of cell-cell junctions, acquisition of
invasive and migratory properties, and expression of mesenchymal cell products such
as fibroblast specific protein-1 (FSP-1), N-cadherin, vimentin, platelet derived growth
factor receptor beta (PDGFRb).26,73,75 These cells can then result in different
mesenchymal cell fates such as fibroblasts and SMC.26,74
The EndMT process is additionally thought to be important for stabilizing the
neovasculature during vasculogenesis and angiogenesis by giving rise to vascular
support cells such as pericytes and/or SMC. Additionally, EndMT plays an important role
in angiogenic sprouting regulated by VEGF.74,76 Through cell lineage tracing, it has been
shown that endothelial cells give rise to SMCs in the medial layer of the coronary arteries,
to stem cell antigen-1 progenitor cells in the adventitial layer, and to ventricular
cardiomyocytes during cardiac homeostasis.77 However, EndMT has also been shown to
be a pathological process in adult valve disease, cardiac fibrosis, cancer fibrosis, and in
myocardial responses to ischemic injury.26,73 In these cases, EndMT results in
pathological consequences such as vascular permeability and tissue fibrosis.
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Figure 1.4 Endothelial to Mesenchymal Transition

EndMT is a process by which the endothelial cells partially lose at least some of their
endothelial cell phenotype, delaminate, and invade into underlying tissues. The process
is marked by the gradual loss of traditional EC markers such as VE-Cadherin, CD31,
p100-catenin, and isolectin-B4, while simultaneously gaining mesenchymal cell marker
expression such as N-cadherin, fibroblast specific protein-1, vimentin, and smooth muscle
a-actin.

TGFb derived from microvascular niche, including enzyme-processed

extracellular matrix or periendothelial cells, is considered one major driving signal of
EndMT.
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1.5.2.1 Partial Endothelial to Mesenchymal Transition
A newly coined term - partial EndMT - describes a partial EndMT which occurs
when one or more of the key characteristics of a complete EndMT are not exhibited, for
example dissolution of cell-cell contacts.76 It has been suggested that partial EndMT could
play a role in angiogenesis, as the tip cells that lead the sprout will lose their apical-basal
polarity, degrade the basement membrane and extracellular matrix, and are migratory.
Throughout this process, it has been additionally shown that Snail is upregulated, a wellknown transcription factor associated with EndMT.78 Studies have also associated partial
EndMT with atherosclerotic lesion development and pulmonary hypertension.79,80
1.5.2.2 EndMT and the TGFb Pathway
The mechanism by which EndMT induction occurs is complex, involving many
different pathways. Studies are beginning to fill in the blanks but much is still unknown
with regards to signaling pathways in EndMT. TGFb, Wnt, CAV1, Shh, Notch1, hypoxia
and ET-1 have also been shown to contribute to EndMT.26,73,74,81,82 For the purposes of
this thesis, the main pathway of interest is TGFb signaling through SMADs.
TGFb is a multifunctional growth factor that can regulate a broad range of biological
processes including cell proliferation, cell differentiation, cell apoptosis, and cell migration.
The TGFb signaling is mediated by the binding of members of the TGFb family binding
specific transmembrane receptors. They bind a complex of two type I and two type II
serine/threonine kinase receptors. Upon ligand binding, the type II receptor will
phosphorylate the type I receptor. This will allow the type I receptor to phosphorylate
specific transcription factors called the receptor regulated (R)- SMADs. When activated,
the R- SMADs form a heteromeric complex with the common mediator (Co)- SMAD
(SMAD4). These heteromeric complexes traffic into the nucleus where they regulate the
transcription of target genes.83 Inhibitory SMADs inhibit the activation of R- SMADs by
competing for the type I receptor interaction. They additionally recruit phosphatases and
ubiquitin ligases to the activated receptors complex leading to dephosphorylation or
proteasomal degradation of the receptor complex (Figure 1.5). In addition to the type I
and type II receptors, there are the co-receptors (also called TGFb receptor III), endoglin
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and betaglycan. These co-receptors do not signal by themselves since they lack
intracellular enzymatic domains. However, they increase the ligand-binding affinity for the
TGFb receptors.84 Endoglin is highly expressed in proliferating endothelial cells.
Following the translocation of the heteromeric complexes of SMADs into the
nucleus, the SMAD complexes interact with transcriptional co-activators and/or corepressors to activate or repress transcription of TGFb target genes which can encode
EndMT. The SMAD complexes not only activate expression of EndMT genes but also
increase the activity of EndMT transcription factors. For example, SNAI1’s transcription
is SMAD3-dependent, whereas SNAI2 (SLUG) is induced indirectly by the SMAD3induced expression of myocardin-related transcription factor (MRTF). SMADs directly
activate the expression of some mesenchymal genes, for example, those encoding
fibronectin, vimentin, and Pro-a(I)-collagen. SMAD3-SMAD4 also cooperate with Snail to
repress E-cadherin (VE-cadherin, CD31 in EndMT).85

1.6

Aims of the Thesis
This literature review highlights the important but limited understanding of how the

phenotype of cells in the microvascular wall contribute to muscle ischemia and damage
in the context of CLI.
To address this research gap, the goal of my thesis was to delineate abnormalities
in the arteriole wall in the skeletal muscle of patients with CLI.

The purpose of this study was to delineate abnormalities in the
microvascular wall in critically ischemic skeletal muscle.

I present my data in manuscript format. Using histologic techniques, I describe
changes in the endothelial cell layer of the small arterioles of patients with CLI. I identify
previously unrecognized distinct morphology of narrowed and occluded lumens. I further
establish that this pathological change in endothelial cell morphology is associated with
altered expression and colocalization of key proteins indicating a partial endothelial to
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mesenchymal transition (EndMT). These findings provide new consequence of EndMT
and new insights into the pathology of limb ischemia in patients with CLI.
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Figure 1.5 Endothelial to Mesenchymal Transition Mediated by TGFb Signaling

EndMT is activated by binding of the TGFb ligand to the TGFb Type II Receptor, which
will phosphorylate the TGFb Type I Receptor, which will in turn phosphorylate the
SMAD2/3 complex. SMAD2/3 will then form a heteromeric complex with SMAD4 and
translocate into the nucleus. The SMAD complexes can then activate expression of
EndMT genes and increase activity of EndMT transcription factors.
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CHAPTER 2:

MICROVASCULAR STENOSIS IN CRITICAL LIMB ISCHEMIA: ROLE OF
PARTIAL ENDOTHELIAL TO MESENCHYMAL TRANSITION
2.1

Introduction
Critical limb ischemia (CLI) is a severe manifestation of atherosclerotic peripheral

artery disease (PAD) that can lead to intractable lower limb pain, infection, and nonhealing ulcers.1 In an effort to improve limb perfusion and retain limb viability, surgical
and catheter-based procedures are widely employed. Unfortunately, interventional
success may not translate to clinical improvement.2 Moreover, even with acute clinical
success, long-term failure from recurrent leg ischemia can ensue. Up to 66% of patients
with PAD who have undergone an intervention still require leg amputation.3
This large burden of refractory PAD suggests that there are additional pathological
processes, beyond the narrowing of the large and medium-sized feeder arteries, that
require attention.

Important in this regard is the state of the microvasculature.

Microvascular dysfunction in PAD is increasingly appreciated, with evidence for
decreased nitric oxide signaling,4–6 increased production of endothelin receptors,7 and
decreased arteriolar vaso-responsiveness ex vivo.5,6 There is also evidence that capillary
density can fall modestly (~10%) in PAD skeletal muscle,8,9 although other studies have
identified an increase in capillaries, possibly reflecting an angiogenic response.7,10–13
Importantly, even if angiogenesis proceeds, the function of the neovessels may be
abnormal.14
Notwithstanding these defects, the extent to which impaired microvascular vasoresponsiveness or a modest decline in capillaries can drive CLI, or be a primary cause of
failed revascularization procedures, is uncertain. Importantly, much about the
microvasculature in PAD remains unknown. This includes the structural attributes of the
distal arteriolar tree, a critical network that controls flow into the capillary bed. Despite
their importance, the small caliber of these intramuscular vessels (diameter <40 µm)
makes morphometric assessment challenging. Arterioles of this size are comprised of an
endothelial cell monolayer, and one or two layers of smooth muscle cells (SMCs).
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However, whether the fundamental cellular structure of the distal arterioles in CLI is
altered, and if so, what those changes are, remains unknown.
Herein, we report the phenomenon of non-atherosclerotic, non-thrombotic
narrowing of small arterioles within the skeletal muscle of critically ischemic limbs from
individuals with CLI. We further identify that the pathological restructuring of these distal
arterioles arises from partial endothelial to mesenchymal transition (EndMT). The findings
uncover a previously unrecognized microvascular closure process that could underlie the
debilitating consequences of critical limb ischemia.
2.2

Methods
2.2.1 Specimen Collection
All human tissue samples and patient information were collected with written,

informed consent from patients using protocols approved by the Western University
Review Board for Health Sciences Research Involving Human Subjects and in
accordance with the 1964 Declaration of Helsinki. Specimens were collected from the
skeletal muscle of 10 individuals (6 female, 4 male) with CLI, immediately following below
or above knee amputation (9 bellow-knee and 1 above-knee amputation). For each
patient, skeletal muscle specimens 1 cm by 1 cm by 0.5 cm were harvested from both the
proximal and distal tibialis anterior muscle and/or the gastrocnemius muscle, yielding 24
samples in total.
Non-PAD muscle specimens were collected from 6 individuals (4 female, 2 male)
without PAD or muscle diseases. Two specimens were from the tibialis anterior muscle
(purchased from Amsbio following institutional review board approved protocols) and four
specimens were collected by needle biopsy of the vastus lateralis within 24-hrs of death.
2.2.2 Histology and Immunostaining
Skeletal muscle samples were fixed in 10% formalin for 48 hours, embedded in
paraffin, and 5-µm thick cross-sections were stained with hematoxylin and eosin and
Mason’s trichrome. For immunofluorescence detection sections, were subjected to heatmediated antigen retrieval with citrate buffer. Endothelial cells were identified using one
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of two different anti-CD31 antibodies, selected to enable double and triple immunolabeling as required. Smooth muscle cells (SMCs) were likewise detected using one of
two anti-smooth muscle (SM) a-actin antibodies, to enable appropriate combinatorial
immuno-labeling.

The antibodies employed and the optimized combinations are

delineated in Appendix B and C.

Nuclei were visualized with 4’,6-diamindino-2-

phenylindole (DAPI) Fluoromount-G (SouthernBiotech, 0100-020).14 Fluoresce images
were acquired using a Nikon A1 hybrid laser-scanning confocal microscope (Galvano
scanning, lasers 405, 488, 561, and 640 nm excitation wavelengths, as appropriate) using
NIS Elements software. Microvascular density quantification was obtained using the BX51 with RETIGA EXi Mono 12-bit camera (QImaging) and captured with Northern Eclipse
(EMPIX Imaging Inc.). Fluorescent signals were quantified using Leica Aperio VERSA
Fluorescence Pathology Scanner (40x objective, z-stack range 1.2 µm with a step size of
0.2 µm). Specific arteriolar morphology quantification was quantified with Carl Zeiss
Imager M2m microscope and AxioCam HRm camera captured by AxioVision (Zeiss)
Software. Bright field images were scanned using Leica Aperio AT2 bright field scanner
(20x objective).

2.2.3 Analysis of Skeletal Muscle Pathology
Full section scans of hematoxylin and eosin and Mason’s trichrome-stained muscle
tissues were obtained using a Leica Aperio AT2 bright field scanner. Scanned sections
were evaluated using Aperio ImageScope slide viewing software (Leica Biosystems) for
myocyte atrophy, myocyte degeneration, central or internal nuclei, interstitial
inflammation, and endomysial fibrosis. Myocyte atrophy was determined by hematoxylin
and eosin staining and assessed based on shrunken myofibers with either rounded or
sharply angular cross-sectional borders. Myocyte necrosis was based on pale eosin
staining and mononuclear cell infiltration.

The interstitial pathological attributes

(inflammation and fibrosis) were ranked on a severity scale of 0 – 3. The myofiber
attributes (atrophy and necrosis) were categorized on area scale of + to +++,
corresponding to <30%, 30-60%, or >60% of tissue section area, respectively. Internal
nuclei were identified as present or not.
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2.2.4 Analysis of Capillary and Arteriole Density
Capillary density was quantified in 5-10 equally spaced, randomly selected, 60x
objective fields from all samples using ImageJ (NIH). Capillaries (<8 µm in diameter) were
identified using CD31 immunostaining. Arterioles (8-60 µm in diameter) were identified
in sections co-immunolabeled with CD31 and smooth muscle (SM)-a-actin.

2.2.5 Analysis of Arteriolar Morphometry
Arteriole (8-60 µm in diameter) morphology was quantified from sections imaged
by widefield microscopy (Carl Zeiss Imager M2m microscope) with AxioVision (Zeiss)
Software. The lumen area (area within the inner endothelial cell border, µm2) and vessel
size (circumference at the outer endothelial cell border, µm) of all cross-sectioned
arterioles were measured from 8-15 equally spaced, randomly selected, 40x objective
fields of view of CD31 stained sections, using ImageJ (NIH). Fractional endothelial cell
area was defined as the endothelial cell area divided by the area bound by the outer
endothelial cell border. All endothelial cell measurements were made manually and
based on individual CD31 channel. To establish the range of fractional endothelial cell
areas within non-PAD arterioles, and recognizing this would vary depending on arteriolar
size, a 90% prediction band was generated (see Statistical Analysis). Arterioles were
considered to have lumens narrowed by endothelial cells if the fractional endothelial cell
area was above the 90% prediction band. The endothelial cell nuclei aspect ratio
(tangential and orthogonal to the vessel border) was determined from DAPI-stained
tissues and measured using ImageJ (NIH).
2.2.6 Analysis of N-cadherin and EndMT
The mean intensity of N-cadherin signal in CD31 positive endothelium of arterioles
was measured from 10-15 equally spaced, randomly selected, 40x objective fields of view
using ImageJ (NIH). All sections were imaged by Carl Zeiss Imager M2m microscope
and captured under identical imaging parameters with AxioVision (Zeiss) Software.
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To quantify S100A4 and Snail expression, the respectively immunostained slides
were scanned (Leica Aperio VERSA) to cover approximately 25 mm2 of tissue. The
percentage of arterioles positive for either S100A4 or Snail, each co-localizing with CD31,
was determined from a mean of 35 randomly selected arterioles per tissue sample. The
proportion of S100A4- or Snail-positive arterioles was categorized based on whether the
arteriole had a narrowed lumen or open lumen, based on luminal closure criteria
described above.
2.2.7 Assessment of TGFb Signaling In Situ
For quantification of TGFb1 expression and abundance of activated, nuclear
pSMAD2/3, immunostained slides were scanned (Leica Aperio VERSA). The intensity of
TGFb1 staining in arterioles was measured from a mean of 25 randomly selected vessels
per sample. The mean pixel intensity and event area was measured using the Aperio
Area Quantification FL Algorithm to calculate the integrated intensity of TGFb1 intensity.
The integrated density (product of the mean pixel intensity and event area for each vessel)
was averaged for each sample. For the TGFb co-receptor, Endoglin, sections were
imaged using laser scanning confocal microscopy and qualitatively assessed.
The percentage of arterioles with CD31-positive endothelial nuclei containing
pSMAD2/3 foci was determined for arterioles. A mean of 25 randomly selected vessels
per sample from the scanned tissue images were evaluated and endothelial pSMAD2/3positive arterioles categorized based on lumen caliber, as above.
2.2.8 Statistical Analysis
All data were non-normally distributed, as assessed using D’Agostino and Pearson
omnibus normality test, and therefore are presented as median and interquartile range
(IQR). Comparisons of two groups were evaluated by Mann-Whitney test (non-paired
analysis), or Wilcoxon matched-pairs test (paired analysis). Multiple (non-parametric)
comparisons of lumen area of arterioles of different calibers were corrected using the
Bejamini-Hochberg procedure to control the false discovery rate at a level of 0.05. To
define an upper limit for the EC area of a normal arteriole of a given size, we plotted the
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fraction of area occupied by the endothelial cells against the area bound by the outer
endothelial cell border in non-PAD arterioles (20-60 µm in outer EC circumference, n =
45 arterioles). Arterioles from the CLI samples were determined to have a thickened
endothelial cell monolayer with a narrowed lumen if the factional endothelial cell area fell
above the upper 90% prediction band. Relationships between skeletal muscle pathology
and arteriole lumen narrowing was tested using a multiple linear regression analysis.

2.3

Results
2.3.1 Clinical Characteristics
To elucidate the microvascular pathology in skeletal muscle in individuals with

critical limb ischemia (CLI), 24 muscle samples were collected from below or above-knee
amputation specimens of 10 patients (6 female, 4 male). Demographic and clinical
features are depicted in Table 2.1. All PAD patients had a Rutherford category six level
of ischemia and the mean age was 65±16 years. Eighty percent of patients had a history
of smoking, 20% had type 1 diabetes, and 60% had type 2 diabetes. Half of the patients
had prior revascularization procedures on the amputated limb (Table 2.1). Lower-limb
muscle specimens from six individuals (4 females, 2 males, mean age 52±17) without
PAD were also studied.

2.3.2 Diverse Pathology in the Skeletal Muscle of Individuals With CLI
Hematoxylin and eosin and Mason’s trichrome stains revealed that all 24 CLI
samples had evidence for myofiber atrophy, evidenced by shrunken myofibers with either
rounded or sharply angular cross-sectional borders (Figure 2.1). This contrasted with the
polygonal cross-sectional morphology, with less angular corners, of myofibers in nonPAD samples (n = 6). Overt myofiber necrosis was found in 18 of 24 samples (from 9 of
10 patients). As well, 16 of 24 samples displayed at least one myofiber with a centralized
or internal nucleus, suggesting a degree of myocyte regeneration. Inflammatory cell
infiltration into the endomysium compartments was evident in 18 of 24 samples, with all
patients having at least one muscle region with interstitial inflammation. Fibrosis was
evident in 14 of 24 samples, from 7 of 10 patients. The severity of each of these

41

Table 2.1 Cohort Demographics

† Prior
*Diabetes Smoking Revascularization
Procedures
N
Y
Y
N
Y
Y

Patient

Sex

Age

1
2

M
F

60
31

3

M

57

T1

Y

N

4

M

72

T1

Y

N

5

F

79

T2

N

Y

6

F

68

T2

Y

N

7

M

90

T2

Y

N

8

F

74

T2

Y

Y

9

F

67

T2

N

Y

10

F

50

T2

Y

N

Muscles Harvested
Gastrocnemius
Gastrocnemius
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal
Gastrocnemius
Tibialis Anterior Proximal
Tibialis Anterior Distal

*T1 – Type 1 diabetes, T2 – Type 2 diabetes
† Revascularization procedures on the same leg as was amputated
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Figure 2.1 Histopathology of Human Skeletal Muscle in Patients with CLI

A-C. Hematoxylin and eosin-stained sections of a non-PAD muscle (A, vastus lateralis),
and CLI muscles (B, patient 1 gastrocnemius, C, patient 3 tibialis anterior). CLI muscle
tissues contain angular, shrunken myofibers (asterix), interstitial inflammation (arrow),
central nuclei (arrow head), severe necrosis and degeneration (x), and infiltrating
inflammatory cells (black arrow). D-F. Mason’s trichrome-stained sections of a non-PAD
muscle (D, vastus lateralis), and CLI muscles (E and F, tibialis anterior, patient 7 and
patient 3). The latter demonstrate mild interstitial fibrosis and severe scarring and fibrosis,
respectively. Images were captured with Olympus BX-51 using Northern Eclipse (EMPIX
Imaging Inc.) software.
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pathological findings was variable, both between patients and among different samples
from the same patient (Table 2.2).
2.3.3 Capillary and Arteriole Densities are Increased in the Skeletal Muscle
of Individuals with CLI
To evaluate the skeletal muscle microvascular content, sections were doubleimmunostained for the endothelial cell marker, CD31, and the smooth muscle cell marker,
smooth muscle a-actin (Figure 2.2 A-B, Figure 2.3 A-B). Notably, capillary density (< 8
µm diameter) in the CLI muscles was 1.8-fold higher than that in the non-PAD muscles
(*p=0.009, Figure 2.2 C). Interestingly, the density of small arterioles (8-60 µm diameter)
was also significantly increased in CLI samples (*p=0.0002, Figure 2.3 C). These findings
suggest that, rather than there being a net loss of microvessels, the CLI musculature
underwent an angiogenic response.

2.3.4 Arteriolar Stenosis: Endothelial Cell Rounding and Thickening
While scrutinizing the microvascular morphology, we observed small arterioles
within CLI muscle samples in which the endothelial cells abnormally encroached the
lumen. As illustrated in Figure 2.4 A, double immunostaining for CD31 and smooth muscle
a-actin revealed a range of small arteriolar morphologies in CLI skeletal muscle. This
included arterioles with flattened endothelial cells and an open lumen, arterioles with more
rounded endothelial cells and a narrowed lumen, and arterioles with lumens completely
occluded by bulky endothelial cells. Narrowed or occluded lumens were mostly
appreciable in arterioles ≤20 µm in diameter (as assessed from the outer endothelial cell
border).
Quantitative analysis revealed that for a given arteriolar size, based on the outer
endothelial cell circumference, the lumen area of PAD arterioles was significantly less
than that of non-PAD arterioles, and reduced by at least 40% (Figure 2.4 B). As well, the
area of the endothelium, expressed related to the area bounded by the outer endothelial
cell border was 1.2-fold greater (*p<0.0001) for arterioles in the skeletal muscle of CLI
patients (Figure 2.4 C), indicating a thickened endothelium largely responsible for the
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Figure 2.2 Increased Capillary Density in the Skeletal Muscle of Patients with CLI

A-B. Fluorescence micrographs of human skeletal muscle immunostained for CD31
showing capillaries (arrows) between myofibers (dotted lines) in a non-PAD muscle (A,
tibialis anterior) and an increased capillary density in a CLI muscle (B, patient 8,
gastrocnemius). C. Graph of data from all muscle samples showing increased capillary
density in CLI skeletal muscle (n=6 non-PAD samples; n=24 CLI samples, *p=0.0049).
Images were captured with Olympus BX-51 using Northern Eclipse (EMPIX Imaging Inc.).
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Figure 2.3 Increased Arteriole Density in the Skeletal Muscle of Patients with CLI

A-B, fluorescence micrographs of human skeletal muscle immunostained for CD31(red)
and SM a-actin (green) showing arterioles (arrows) in a non-PAD muscle (A, vastus
lateralis) and an increased arteriole density in CLI muscle (B, patient 5, tibialis anterior).
C. Graph of data from all muscle samples showing increased arteriole density in CLI
skeletal muscle (n=6 non-PAD samples; n=24 CLI samples, *p=0.0002).

49

A
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25 µm
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SM-α-actin CD31 DAPI

25 µm

CLI

C
*p = 0.0002

Arteriole Density (/mm 2)

60

40

20

0

Non PAD

CLI

50

Figure 2.4 Arteriolar Stenosis in CLI muscle and its association with Endothelial
Cell Rounding and Thickening

A.

Confocal microscope image projections of arterioles in human skeletal muscle

immunostained for CD31(red) and SM a-actin (green) (~ 4.5 µm z stack, 0.125 µm steps).
Upper row depicts arterioles of sizes corresponding to distal non-terminal arterioles and
lower row depicts smaller arterioles corresponding to terminal arterioles.

Non-PAD

arterioles have a flattened endothelial monolayer and open lumen. In CLI arterioles, the
endothelial monolayer can be flattened, or thickened with endothelial cell re-orientation,
resulting in a narrowed or entirely occluded lumen. (See online video supplement,
Appendix D). B. Quantitative data for lumen size of non-PAD and CLI arterioles (area
within the inner endothelial cell border), binned based on overall vessel size
(circumference at the outer endothelial cell border). (n=45 non-PAD arterioles, n=391 CLI
arterioles, *p=0.0014). C. Fractional endothelial cell area (endothelial cell area divided
by the area bound by the outer endothelial cell border) in small arterioles (n=45 non-PAD
arterioles, n=391 CLI arterioles, *p<0.0001). D. Graph of endothelial cell orientation,
determined from endothelial cell nucleus aspect ratio (n=119 non-PAD endothelial cells,
n=1450 CLI endothelial cells, *p<0.0001).
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lumen narrowing. The endothelial cells themselves were rounded and protruding into the
lumen of the vessel. This was associated with reorientation of the endothelial cell nucleus.
The nuclear aspect ratio (tangential and orthogonal to the vessel border) was 1.9 in nonPAD arterioles and 1.2 (*p<0.0001) in CLI arterioles (Figure 2.4D).
To quantify the prevalence of pathological arteriolar narrowing, we established a
90% prediction band based on arterioles (n=45) within skeletal muscle of non-PAD
patients (endothelial cell area vs vessel area). This revealed that 9% of the small
arterioles within skeletal muscle of patients with CLI showed a complete occlusion, 33%
had narrowed lumens, and 58% had an open lumen. Multiple linear regression analysis
did not reveal a relationship between any myofiber pathology and proportion of affected
arterioles in a given sample (p>0.138).

2.3.5 Obstructive Endothelial Cells Have Increased and Atypically Localized
N-cadherin
N-cadherin is diffusely expressed in the membrane of microvascular endothelial
cells and participates in endothelial cell-mural cell anchorage.15,16 Given the striking shift
in endothelial cell morphology in arterioles of CLI muscle, including greater contact area
between endothelial cells, we asked if the content or distribution of N-cadherin was
altered. We double-immunolabeled sections for CD31 and N-cadherin. In the arterioles
of non-PAD muscle, we observed weak, diffuse signals of N-cadherin in endothelial cells
(Figure 2.5 A), consistent with previous reports.15 However, there were marked
differences in endothelial cells of CLI arterioles. First, the mean N-cadherin content was
increased by 2.5-fold (*p=0.0007) (Figure 2.5 A, B). As well, among CLI arteriole
endothelial cells, the N-cadherin abundance was higher (1.3-fold, *p=0.0001) in those
with a narrowed or occluded lumen than those CLI arterioles that still maintained an open
lumen (Figure 2.5 C).
Also striking was that N-cadherin was found concentrated and localized at
endothelial cell-cell junctions. This was evident at the lateral interface between adjacent
endothelial cells and also at the apical interface of two opposing and contacting
endothelial cells among vessels in which the lumen was entirely occluded. This latter
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Figure 2.5 Endothelial Cells in Stenotic Arterioles Have Increased Expression and
Apical and Junctional Localization of Mesenchymal Marker N-cadherin

A, Confocal micrographs of human skeletal muscle arterioles immunostained for CD31
(red) and N-cadherin (green). Whereas the N-cadherin signal is diffuse in the endothelial
cells of the non-PAD arteriole, there is enhanced N-cadherin signal in the endotheila cells
of the CLI arterioles, with pronounced localization at both side-to-side and apex-to-apex
intercellular junctions (middle row, arrows) and also at the apex of inwardly protruding
endothelial cells that have fully occluded the arteriole (bottom row). B-C. Plots of Ncadherin signal in endothelium of non-PAD and CLI arterioles (B, n=6 non-PAD samples;
n=24 CLI samples, *p=0.0103) and endothelium of CLI-open lumen and CLI-narrowed
lumen arterioles (C, n=24, *p<0.0001).
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finding suggested an active role for N-cadherin junctions in occluding arterioles in CLI
limbs. Intriguingly, apical endothelial cell N-cadherin complexes were also found in
arterioles in which endothelial cells protruded well into the lumen but without fully
contacting the opposing endothelial cell.

2.3.6 Obstructive Endothelial Cells Have Undergone a Partial Endothelial to
Mesenchymal Transition
In addition to its role in cell-cell adhesion, N-cadherin is known to mark the process
of EndMT.17 Therefore, we next determined if the morphologic change in endothelial cells
within the arterioles was indeed associated with a partial EndMT. For this, we
immunolabeled the skeletal muscle sections for CD31 to identify the endothelium along
with the mesenchymal cell marker S100A4, and the EndMT-related transcription factor,
Snail. Each of these markers were evaluated for their immunoreactivities in endothelial
cells of the non-PAD and CLI specimens.
There was a 2-fold increase in the number of arterioles in the CLI muscle which
exhibited diffuse S100A4 staining compared to non-PAD muscles (*p=0.0059) (Figure 2.6
A, B). Additionally, the percentage of S100A4-positive vessels was further increased in
the CLI narrowed lumen vessels compared to the open lumen vessels (7.4-fold
*p<0.0001) (Figure 2.6 C).
Similarly, endothelial cells within the non-PAD arterioles were mostly negative for
nuclear transcription factor staining with Snail. However, 75% of the arterioles studied
within the CLI muscle showed punctate, nuclear Snail staining (*p=0.0002) (Figure 2.7 A,
B). Further analysis showed that there was a 2.6-fold increase (*p<0.0001) in the
percentage of vessels expressing nuclear Snail when comparing the CLI narrowed lumen
vessels to the open lumen vessels (Figure 2.7 C).
Together, these findings strongly indicate the process of partial EndMT in the
small intramuscular arterioles within skeletal muscle of CLI patients, associated with
narrowing or overt occlusion of these vessels.
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Figure 2.6 Rounded Endothelial Cells Have Expression of Mesenchymal Markers
S100A4

A. Confocal micrographs of human skeletal muscle arterioles immunostained for CD31
(red) and S100A4 (green), showing cytoplasmic S100A4 signal in endothelial cells of a
CLI arteriole with a narrowed lumen (arrow), but not in endothelial cells of control, nonPAD arteriole.

B-C. Graphs showing the proportion of endothelial S100A4-positive

arterioles in non-PAD and CLI samples (B, n=6 non-PAD samples; n=24 CLI samples,
*p=0.0059) and the proportion of S100A4-positive arterioles in CLI-open lumen and CLInarrowed lumen arterioles (C, n=24, *p<0.0001).
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Figure 2.7 Rounded Endothelial Cells Have Expression of EndMT Transcription
Factor Snail1
A. Confocal micrographs of human skeletal muscle arterioles immunostained for CD31
(red) and Snail1 (green), showing punctate Snail1 signals in the nucleus of endothelial
cells in a CLI arteriole with a narrowed lumen (arrow).

B-C. Graphs showing the

proportion of endothelial Snail1-positive arterioles in CLI samples (B, n=6 non-PAD
samples; n=24 CLI samples, *p=0.0002) and the proportion of Snail1-positive arterioles
in CLI-open lumen and CLI-narrowed lumen arterioles (C, n=24, *p<0.0001).
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2.3.7 Obstructive Endothelial Cells Display Increased Transforming Growth
Factor Beta (TGFb) Signaling
TGFb signaling regulates endothelial cell phenotype and plays an important role
in the progression of EndMT18 process by activating expression and increasing the activity
of EndMT transcription factors.19 To determine if endothelial cells in CLI arterioles were
receiving TGFb signals, sections were immunolabeled with pSMAD2/3. There was
evidence for pSMAD2/3 in both non-PAD and CLI arterioles. However, there was a 1.4fold increase (*p=0.0078) in the punctate, endothelial cell nuclear staining in the CLI
samples (Figure 2.8 B). Notably, the CLI arterioles with a narrowed lumen showed a
particularly increased percentage of arterioles positive for pSMAD2/3 (7.9-fold,
*p<0.0001) (Figure 2.8 C). These findings implicate an enhanced TGFb-induced signaling
and gene-expression cascade in CLI arterioles.
2.3.8 Transforming Growth Factor Beta (TGFb) Upregulation in CLI
To determine the content and location of TGFb ligand in the CLI samples, sections
were stained for TGFb1. The mean expression of TGFb1 was increased 63-fold in the
arterioles of CLI samples compared to the non-PAD samples (Figure 2.9 B). Notably, the
upregulation was primarily found in the smooth muscle cells (Figure 2.9 A). Interestingly,
this expression pattern was not limited to the arterioles with narrowed lumen but could be
seen in arterioles with open lumens as well (data not shown). This expression was also
not limited to the vessels within the 20-60 µm in outer endothelial cell circumference size
range (data not shown), although for the purposes of this analysis this was the size range
evaluated. To determine if there was differential receptivity of endothelial cells for TGFb
signaling between non-PAD and CLI tissues, we stained for the TGFb co-receptor,
Endoglin. We found qualitative evidence for Endoglin up-regulation in the endothelial cells
of arterioles in skeletal muscle of patients with CLI (Figure 2.10).
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Figure 2.8 Phospho-SMAD 2/3 Activation in Rounded Endothelial Cells

A. Confocal micrographs of human skeletal muscle arterioles immunostained for CD31
(red), pSMAD2/3 (green), showing discrete pSMAD2/3 punctate signals in the nucleus of
endothelial cells within the CLI arteriole (arrow). B-C. Graphs depicting the percentage
of pSMAD2/3-positive arterioles in non-PAD and CLI samples (B, n=6 non-PAD samples;
n=24 CLI samples, *p=0.0078) and in CLI narrowed lumen arterioles compared to those
with open lumens (C, n=24, *p<0.0001).
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Figure 2.9 Transforming Growth Factor b1 (TGFb1) Activation in Smooth Muscle
Cells of CLI Arterioles

A. Confocal micrographs of human skeletal muscle arterioles triple-immunostained for
CD31 (red), SM a-actin (green), and TGFb1 (white). There is increased TGFb1 signal
in the vascular smooth muscle cells of the CLI arteriole (arrow). B. Graph showing
substantially increased TGFb1 expression in smooth muscle cells of CLI arterioles (n=6
non-PAD samples; n=24 CLI samples, *p=0.0002).
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Figure 2.10 Endoglin Expression in Endothelial Cells of CLI Arterioles

Confocal micrographs of human skeletal muscle arterioles triple-immunostained for CD31
(red), SM a-actin (green), and Endoglin (white), showing increased Endoglin expression
in the endothelial cells of the CLI arteriole (arrow).

66

67
2.4

Discussion
Peripheral artery disease is primarily considered a disease of the large vessels.

While atherosclerosis is the driving process, the microvascular determinants of refractory
PAD and CLI remain poorly understood. In this study, we report a novel form of arteriolar
stenosis in individuals with CLI, wherein the endothelial cells obstruct the lumen. This
phenomenon was found to arise from pronounced rounding and thickening of endothelial
cells, a morphological shift that was associated with partial endothelial to mesenchymal
transition. Notably, this endothelial cell pathobiology affected the smallest arterioles,
those less than 20 µm in diameter, with 42% being significantly narrowed and 9% being
completely occluded. This high burden of arteriolar closure points to an important, but
previously unrecognized, process in CLI.
The finding of arteriolar lumen narrowing due to bulky endothelial cells in patients
with CLI is remarkably different from the lumen narrowing from atherosclerotic disease.
The broad phenomenon of arteriolar stenosis is not new and has been recognized in a
number of conditions. This includes (1) vasculitis,20,21 (2) transplant vasculopathies,23 (3)
thromboembolic disease,24–26 and (4) cholesterol emboli.21 However, neither leukocyte
infiltration or fibrinoid changes, hallmarks of vasculitis,21,22,27 were evident on the CLI
arterioles studied, nor was there evidence for microaneurysms, thrombi or cholesterol
emboli. Instead, the rounded and re-oriented microvascular cells themselves, specifically
the endothelial cells, were occluding the lumen.
Interestingly, the phenomenon of arteriolar occlusion in individuals with severe
PAD and CLI has been recognized. Casting studies in the 1960’s revealed that, in legs
of individuals with CLI, there were arterioles of diameter 10-100 µm that were seen to be
occluded.26,28 However the true nature of the casting findings remained unknown and,
perhaps because of this, the phenomenon appears to have lost traction as a
pathophysiologic consideration in CLI. Although we cannot be sure if the occluded lumens
in these early studies were due to endothelial cell plugging, the findings, together with the
high prevalence of arteriolar obstruction identified in the muscles studied herein,
consolidate arteriolar obstruction as an entity warranting further investigation.
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Our finding of EndMT leading to luminal encroachment is a novel outcome of
EndMT. The classical outcomes of EndMT are endothelial cells gaining invasive abilities,
delaminating and sprouting or egressing off the vessel wall.17,29 However, evidence is
emerging that EndMT can exist on a spectrum, where the final expression and cell
phenotype adopted can vary widely. The concept of partial EndMT reflects this spectrum,
and is employed when at least one of the key characteristics of complete EndMT is not
exhibited.30 The obstructing endothelial cells maintained CD31 expression, while
acquiring mesenchymal attributes indicated by the mesenchymal markers S100A4 and
Snail, and expressing N-cadherin to a significantly higher extent than control arterioles.
Intriguingly, in addition to expressing CD31, these altered cells remained on the luminal
side of the vessel and maintained cell-cell contacts. Thus, although the phenotype is
unique, collectively the findings strongly support a phenomenon of partial EndMT.
The reason why partial-EndMT in the CLI limbs resulted in the inward positioning
of endothelial cells towards the lumen, in contradistinction from sprouting off the vessel,
is unknown. It is possible that, in the context of the ischemic and damaged tissue, the
endothelial cells were effectively trapped on the luminal side of an arteriole thickened by
extracellular matrix accumulation,31 effectively confining the basal surface of the
transitioning endothelial cells in place. Thus, the arteriolar constituents could halt or
otherwise modify the typical progression of EndMT, leading to bulky endothelial cells
occluding arterioles.
In addition to the EndMT marker upregulation in the obstructing endothelial cells,
we also noted an interesting change in N-cadherin localization. Specifically, N-cadherin
shifted from a diffuse expression signal, consistent with its dispersion on the endothelial
cell membrane,15,32 to discrete N-cadherin-containing junctions between adjacent
endothelial cells and, in some cases, opposing endothelial cells (Figure 2.4a). Typically,
N-cadherin does not act as a junctional molecule for endothelial cell-endothelial cell
interactions, a role widely known to be accomplished by VE-cadherin.

Instead, N-

cadherin in the endothelium it is considered to mediate endothelial-mural cell
interactions.16

This shift in N-cadherin location and function is consistent with the
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established phenomenon of cadherin switching.16 Importantly, N-cadherin is involved in
cytoskeletal remodeling, including cortical actin regulation in epithelial cells.33
The finding of apical N-cadherin in endothelial cells of the occluded or narrowed
arterioles is also noteworthy. A number of studies have demonstrated an evolutionarilyconserved apical enrichment of N-cadherin in developing neural tube. Loss of this Ncadherin subcellular localization has been associated with defects in neuroepithelial
morphogenesis, including failed neural tube closure and disrupted neuroepithelial
cytoarchitecture.34–38 Although these studies were not in endothelial cells, epithelial cells
have similar characteristics such as polarity, specialized cellular shape and orientation.
The localization of N-cadherin at endothelial cell junctions could be a new mode of
cadherin switching. Whether it is associated with a decrease in VE-cadherin remains
unknown. However, the specific localization of N-cadherin within the occluded arterioles
strongly suggests both implications for cytoskeletal remodeling, and N-cadherin mediated
“gluing” of the partially-transitioned endothelial cells, both side-to-side and apex-to-apex
across the lumen of arterioles.
Our finding of increased TGFb1 in SMCs of patients with CLI supports TGFb
signaling pathway-induced EndMT. It is known that SMCs can increase their TGFb1
expression in patients with CLI, but the implications of this have yet to be fully
elucidated.31 The TGFb signaling pathway is a characterized driver of EndMT,17,39 further
supporting a potential TGFß-arteriolar occlusion axis in patients with CLI. Based on the
increased nuclear expression of SMAD2/3 in the obstructive endothelial cells, as well as
the increased expression of co-receptor Endoglin, we propose that TGFb signaling
constitutes a disease promoting EndMT pathway in CLI.
There was no correlation found between myofiber damage and the number of
affected arterioles in a given sample. However, this is not surprising as the site of hypoxia
and ischemic damage will be downstream of the site of arteriolar pathology. It will
however be interesting to ascertain if partial-EndMT-associated arteriolar stenosis
proceeds in individuals at earlier stages of PAD. This is particularly important because
only about 1-2% of patients with intermittent claudication will progress to CLI1 and at
present it’s not possible to identify which patients will remain stable or escalate to limb-
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threatening ischemia. One could speculate that whether or not stable intermittent
claudication will escalate to CLI could in part depend on whether the skeletal muscle
microvasculature is affected by EndMT. The current findings could also have implications
for disease treatment, for example strategies that inhibit EndMT or TGFb1 expression in
the at-risk skeletal muscle.
In conclusion, evaluating the status of the microvasculature in patients with CLI
has brought about the discovery of non-atherosclerotic, non-thrombotic narrowing of
small arterioles. We further identified that the pathological restructuring of these distal
arterioles arises from partial EndMT. The findings uncover a previously unrecognized
microvascular closure process that could underlie the debilitating ischemic damage of
critical limb ischemia.
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3

CHAPTER 3:

GENERAL DISCUSSION AND CONCLUSIONS
The findings presented in this thesis provide new insights into the microvasculature
in the ischemic skeletal muscle of patients with CLI. The skeletal muscle landscape of
CLI patients was found to be heterogeneous, and the pathology included myofiber
atrophy and necrosis, interstitial fibrosis and inflammation, and some myofibers with
internal nuclei. Interestingly, although the skeletal muscle had ischemic injury, both the
capillary density (< 8 µm diameter) and arteriole density (8 – 40 µm diameter) were
increased in the skeletal muscle of patients with CLI. Despite this increased
vascularization, I discovered a pronounced abnormality in the arteriolar wall of these
vessels. Specifically, 42% of arterioles of 8 – 20 µm diameter had a significantly narrowed
lumen, with 9% showed complete occlusion. This arteriolar stenosis was caused by
obstructive, rounded endothelial cells that encroached upon the lumen. Upon further
investigation, it was established that these bulky endothelial cells had a distinct
expression of N-cadherin, with a remarkable localization at the apex and endothelial cellcell junctions. As N-cadherin is known to mark the process of EndMT,1 I further
investigated other EndMT markers, specifically S100A4 and Snail. It became evident
these cells had undergone a partial EndMT. Based on subsequent results from
immunostaining for pSMAD2/3, TGFb1, and the TGFb co-receptor, endoglin, I propose a
TGFb receptor/SMAD signaling pathway as a mediator of this newly discovered partial
EndMT process in CLI (Figure 3.1).

3.1

Microvascular Density in CLI
For over 50 years, the microvasculature has been considered to be one reason

why blood flow is impeded in the critically ischemic limb.2 Over the years the
understanding of the pathology of these small vessels has remained limited and
controversial. Most studies evaluating the microvasculature in patients with CLI have
studied the capillary density, which is considered a surrogate measure for microvascular
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Figure 3.1 Arteriolar Stenosis caused by Endothelial to Mesenchymal Transition

EndMT is activated by binding of the TGFb ligand to the TGFb Type II Receptor, which
will phosphorylate the TGFb Type I Receptor, which will in turn phosphorylate the
SMAD2/3 complex. SMAD2/3 will then form a heteromeric complex with SMAD4 and
translocate into the nucleus. The SMAD complexes can then activate expression of
EndMT genes and increase activity of EndMT transcription factors causing the
transitioning endothelial cell to round up and protrude into the lumen of the vessel. Ncadherin junctions will help seal the obstructive endothelial cells together.
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perfusion.3,4 However, findings have been divergent. Some studies have indicated that
humans have angiogenic capabilities, showing an increase in the capillary and
microvascular density in patients with PAD.5–9 Others have shown no change, or a
decrease in capillary density.10–14 The split field may be attributed to a few factors: (1)
variability in the control groups used, (2) variability in how microvascular density was
measured, and (3) patient-specific variability in angiogenesis (which I address below). My
findings are in accordance with reports that indicated an increase in microvascular
density. In fact, I found both the capillary density and arteriole density to be significantly
increased in patients with CLI.
It should be noted that there is difficulty in obtaining an optimum control
assessment for PAD limbs. As microvascular density is most accurately measured from
histology, a tissue biopsy is necessary. While some studies had the opportunity to harvest
normal controls during lower limb surgery or needle biopsy,6–8,12,13,15–19 others have used
a proximal region in the same patient as a control.20,21 As we and others have shown, the
skeletal muscle of patients with CLI is vastly affected and heterogeneous.22–25 Making the
assumption that the muscle in the proximal region of the patients amputated limb may
create confounding factors and affect angiogenesis related data. For my study, skeletal
muscle was harvested from the vastus lateralis of non-PAD individuals. While there will
remain patient-specific variability in angiogenesis, sampling multiple regions from the CLI
muscles and using different control individuals will help minimize the effects of muscle
heterogeneity on my data.
Capillaries are small and can be difficult to label; therefore, the choice of
endothelial cell marker can also bring about variability in capillary density measurements.
Investigators have taken advantage of different endothelial cell markers, for example
CD31, vWF, or CD34.6–9,12,13,15–19 The most commonly used marker is CD31, which I
made use of in my study. Moreover, the definition for the microvascular density measured
has varied. Some measured microvascular density without defining or distinguishing
between capillaries and small arterioles.7–9 Some measured a capillary to fiber ratio,5,10
and others evaluated the mean capillary density.6,7,12,13 Although both of these
assessments act as a measure of angiogenesis, the fiber-type heterogeneity within
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skeletal muscle requires rigorous procedural attention when selecting histological images
to avoid sampling bias within any given muscle sample.26
Despite the above methodological concerns, the extent of angiogenic response in
patients with PAD has long been the primary and most-widely assessed endpoint. Many
clinical trials for PAD have been based on capitalizing on the natural process of
angiogenesis to re-perfuse the ischemic leg. These attempts at therapeutic angiogenesis
have been met with little success.3 While it is critical to understand the angiogenic
capabilities of critically ischemic skeletal muscle in humans, the functionality of surviving
and growing microvessels in ischemic human muscle is equally, if not more, important.
Studying the cellular and structural components of the microvasculature of these patients
– whether native or regenerated – is an important starting point to understanding this
complex disease. My findings of microvascular density are important in this regard
because they establish that, despite an abundance of small vessels in the limbs of those
with CLI, the structure of these vessels, as discussed below, can be profoundly abnormal.

3.2

Arteriolar Stenosis in Critical Limb Ischemia
Through vessel by vessel examination of the cellular structure of the microvascular

wall in the chronically ischemic skeletal muscle, I discovered a novel form of arteriolar
stenosis, wherein the endothelial cells obstructed the lumen. The finding of arteriolar
stenosis due to bulked-up endothelial cells occluding the lumen in humans constitutes
previously undescribed mode of arteriolar pathology. To date, arteriolar stenosis has been
recognized to arise from: (1) vasculitis;27,28 (2) transplant vasculopathies;29 (3)
thromboemboli;30,31 and (4) cholesterol emboli.28 Small vessel vasculitis refers to the
inflammation of the blood vessel walls and plays a role in many diseases such as ChurgStrauss syndrome, microscopic polyangiitis, and polyarteritis nodosa.27,28 Vasculitis can
be histologically characterized by granulomatous inflammation, leukocyte infiltration, and
fibrinoid changes in the vascular wall.32 Microvasculopathy is the term generally used to
denote a non-inflammatory arteriolar stenosis and can originate from immune complex
deposition, can be associated with tortuosity of small vessels, and organ transplant.28,33
Embolic stenosis can be caused by thrombosis or cholesterol.34 The microvascular
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pathology that I have discovered is entirely novel in humans in that it is the native
microvascular cells, specifically the endothelial cells, that are occluding the lumen. There
was neither inflammatory cells nor emboli involved.
A search of the literature has revealed one study that has detected endothelial cell
pathology that appears similar to what has been noted here. Specifically, a group in
Montreal, Quebec has identified endothelial cell hypertrophy and microvascular occlusion
in horses. Specifically, Dubuc et al. studied abnormal wound repair in horse limbs, a
phenomenon termed proud flesh that is characterized by excessive fibroplasia and
scarring, also known as hypergranulation.35 Their group found that there were
microvessels within the granulation tissue in which the surface area of the endothelial
cells was increased and the lumen was occluded.35 While the reason for this unusual
endothelial cell morphology was not proposed, they suggested the cells may be
apoptosis-resistant. Although this finding was in equine proud flesh and not human PAD,
granulation tissue can be associated with tissue hypoxia, ischemia, and delayed wound
healing. Additionally, other studies have shown an increase in TGFbRI and TGFbRII in
the endothelium of vessels in proud flesh of horses.36 This is an interesting parallel to our
findings of arteriolar stenosis in patients with CLI. It is possible that the hypertrophied
endothelial cells that were found in equine proud flesh underwent a partial EndMT
process homologous to what I have observed in CLI.
It should also be noted that the phenomenon of arteriolar stenosis in human PAD
has previously been identified, but in a limited way and without mechanistic data. In 1967,
Margret Conrad determined that some arterioles from 30 – 100 µm in diameter in patients
with CLI showed occlusion. This was based on casts made of the vasculature.2 With her
method, it was not possible to determine the nature of occlusion, although she suggested
it may be small thrombi.2 It is interesting to speculate that the truncated arterioles that
Conrad showed in her casting images were due to the endothelial cell obstruction in the
terminal arterioles that I have discovered.
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3.3

N-cadherin in Critically Ischemic Arteriolar Endothelial Cells
The bulky endothelial cells I studied in the arterioles of CLI patients had an

interesting N-cadherin localization. Specifically, rather than the diffuse expression within
the endothelial cell membrane that has been well-documented in endothelial cells in
situe,37,38 the localization shifted to discrete N-cadherin junction complexes between
adjacent endothelial cells and, in some cases, between opposing endothelial cells. This
is interesting because N-cadherin typically does not concentrate at endothelial cell
junctions and does not act as a cadherin for endothelial cell-endothelial cell interactions.
That role is widely known to be accomplished instead by VE-cadherin. N-cadherin, on the
other hand, is considered to play a role in endothelial-mural cell junctions.39 Cadherin
switching – i.e. from one type of cadherin to a different one – is understood to play a role
in EMT as well as in endothelial cell invasiveness and cell motility.39 The altered
localization of N-cadherin forming at endothelial cell junctions may be a form of cadherin
switching. Whether it is associated with a fall in VE-cadherin is not yet known. However,
the findings strongly suggest that there is N-cadherin-mediated gluing of the partiallytransitioned endothelial cells both side-to-side and apex-to-apex across the lumen of
arterioles.
N-cadherin is also involved in cytoskeletal remodeling through actin regulation.40
Leonard et al. showed that the assembly of mature N-cadherin junctions along cell-cell
interfaces preceded the organization of a cortical actin cytoskeleton of lens epithelial cells
in the embryonic chicken.40 A number of studies have demonstrated an evolutionarilyconserved apical enrichment of N-cadherin in the developing neural tube, and loss of this
N-cadherin subcellular localization has been associated with defects in neuroepithelial
morphogenesis,

typically

including

failed

neural

tube

closure

and

disrupted

neuroepithelial cytoarchitecture.41–45 Although these studies were not in endothelial cells,
epithelial cells have some similarities to endothelial cells, particularly in respect to their
polarity and specialized cellular shape and orientation. It would be interesting to further
investigate the role of N-cadherin on cytoskeletal remodeling of endothelial cells to see if
increased junctional N-cadherin is associated with cytoskeletal remodelling that mediates
the rounded and bulky endothelial cells (see Future Directions Section 3.6).
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3.4

Partial Endothelial to Mesenchymal Transition in CLI Arterioles
In addition to discovering N-cadherin junctional localization in obstructive

endothelial cells, there was also a general increase in N-cadherin expression. Increased
N-cadherin expression is linked with EndMT.1 Accordingly, I further investigated the
expression profile of EndMT markers in these endothelial cells and found that they had
increased expression of S100A4 and Snail. Collectively, these finding provide strong
evidence for partial EndMT in CLI arterioles.
The classical outcomes of EndMT are endothelial cells gaining invasive abilities
leading to delaminating and sprouting or egressing off the vessel wall.1,46 However,
evidence is emerging that EndMT can exist on a spectrum, where the final endothelial
cell phenotype can vary widely following the transition. For this reason, the concept of
partial EndMT has been developed, and employed to denote when at least one of the key
characteristics of complete EndMT are not exhibited. This could include failure to lose
cell-cell contacts.47 Not only is our discovery the first time EndMT (either partial or
complete) has been pathologically associated with PAD, but the inward bulging of the
endothelial cells is also a new morphologic feature of endothelial cells undergoing a
partial-EndMT.
Typically, pathological assessment of EndMT has relied on co-staining of
endothelial cell markers and mesenchymal cell markers and this is the approach I have
taken. However, this approach has some limitations: (1) immunostaining cannot identify
EndMT if the cells are so far along in the transition that they have entirely lost their
endothelial cell markers; (2) immunostaining reliability is dependent on antibody
specificity and sensitivity; (3) immunostaining interpretation is subject to overlay errors in
light microscopy, where the superimposition of two cells can be misinterpreted as signal
from one cell; and (4) immunostaining is limited in the number of proteins that can be
assessed.48
Due to the nature of our experiments and tissue collection, we are limited to some
extent by these factors. Primarily, we cannot determine if the endothelial cells that have
undergone a partial transition will continue on to eventually delaminate and fully
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differentiate “out” of the endothelial cell state. However, we propose this is unlikely
because of their luminally-inward shift. We note that laser capture of these obstructive
endothelial cells followed by RNA sequencing would allow genome-wide characterization
of these cells and determine if there is a spectrum within the transitioning cells (see Future
Directions Section 3.6). However, this would be a huge technical challenge. Ultimately,
the endothelial cells causing luminal obstruction warrant further study as it would be
exciting to determine the extent and reversibility of the partial EndMT and occlusion
processes in ischemic human muscle.
Finally, it should be noted that although we are reliant on the specificity and
sensitivity of the antibodies used, the laser scanning confocal microscopy that I employed
has allowed for z-stacks with 0.125 µm steps. Confocal microscopy allows the recording
of images at different focal planes, while removing the out-of-focus signal collected. Each
step acquires an image at that specific focal plane. This in turn enabled 3-dimensional
reconstructions at high resolution, providing reliable evidence that we are seeing true
colocalization of cellular markers, as opposed to markers on two superimposed cells (see
online video supplement, 4.4 Appendix D). This approach was also helpful in ensuring
the rounded endothelial cells identified were not circulating leukocytes trapped in a lumen,
which can also express CD31 staining.49

3.5

TGFb Signaling Pathway
TGFb signaling has recently emerged as relevant to the skeletal muscle in the legs

of patients with PAD. For example, Ha et al. explored this phenomenon with regard to
fibroblast accumulation and collagen deposition.50 Corroborating my findings, they noted
that TGFb1 was strongly expressed specifically in the SMCs of the microvessels. They
suggested that this is a result of chronic hypoxia causing damage to the muscle myofibers
which could induce the SMC of the microvessels to increase their TGFb1 expression.50
As noted above, the classical outcomes of EndMT are endothelial cells gaining
invasive abilities resulting in delamination, sprouting or egressing off the vessel wall.1,46
My finding of a partial EndMT resulting in rounded endothelial cells moving toward the
centre of the lumen is unique. I venture that these endothelial cells are undergoing a form
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of a failed EndMT in response to increased TGFb1 expression. It is understood that PAD
results in fibrosis of microvessels with both collagenous thickening of the capillaries and
muscularization and fibrosis of normally non-muscularized microvessels.8,50,51 I speculate
that this thickening and fibrosis effectively traps the transitioning endothelial cells within
the arteriole lumen, halting or modifying the typical progression of EndMT and resulting
in an occluded vessel.
My finding of increased content of the ligand TGFb1 in SMCs and increased
pSMAD2/3 and Endoglin in endothelial cells in muscle of patients with CLI supports TGFb
signaling pathway induced-EndMT. TGFb has been recognized as a dominant driver of
EndMT during development and pathogenesis of a number of human diseases, including
fibrosis of multiple organs, pulmonary arterial hypertension, brain vascular malformation,
and transplant vascular graft rejection.48 It is interesting to note that vascular SMC can
have increased TGFb1 in patients with CLI, but the implications of this have yet to be fully
elucidated.52 While the causal role of the TGFb signaling pathway in EndMT in ischemic
muscle of patients with CLI requires further investigation using ex vivo cell or animal
models, my current study provides strong evidence for an intriguing novel model of
EndMT driven by paracrine/juxtacrine signaling of SMCs.

3.6

Future Directions
The findings of (1) arteriolar stenosis by obstructing endothelial cells; and (2) the

association of partial-EndMT in CLI both require further investigation because of their
novelty and importance with regard to delineating the mechanisms of the disease.
To further study the obstructing endothelial cells, it is important to further
characterize their expression. As discussed previously, immunohistochemistry has
limitations on the number of markers that can be analyzed. Although laser capture
followed by RNA sequencing would be a technically difficult experiment, it would allow
genome-wide characterization of these cells and determine if there is a spectrum within
the transitioning cells.
It is also important to further investigate the role of N-cadherin on cytoskeletal
remodeling of endothelial cells to see if increased junctional N-cadherin is associated with
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cytoskeletal remodeling that mediates the rounded and bulky endothelial cells.
Additionally, the concept of N-cadherin-mediated “gluing” of opposing endothelial cells
raises entirely new questions regarding adherens junctions, warranting further
exploration. It would also be important to determine if the vessel occlusion is reversible,
as this could implicate possible new therapeutic strategies in some CLI patients. This
assessment would require developing an in vivo or microfluidic model of arteriolar closure
caused by endothelial cells.
The association of EndMT in CLI is new and raises some important clinical
questions. Only about 1-2% of patients with intermittent claudication will progress to CLI53
and at present it is not possible to predict the patients in whom disease progression will
escalate and those in whom disease severity will remain constant.

I propose that

progression of a patient’s diagnosis of intermittent claudication to CLI could, in part, be
dependent on the local TGFb environment of the skeletal muscle. If unregulated signaling
from the mural cells is activated, this could promote partial EndMT and microvessel
plugging. This, in turn, could be an important driver of high-grade ischemia in the leg, over
and above flow reduction from upstream narrowing, changing stable PAD to CLI. Studies
in animal models or in humans that allow for tracking the progression from less severe
PAD with open arterioles to endothelial-plugged arterioles would be important in
delineating this proposed ischemic transition. Also, developing a biomarker, either
imaging or biochemical, that would implicate the endothelial cell plugging process could
stand to be an indicator of distal arteriolar health and potentially help clinical decisionmaking.
Finally, in addition to TGFb1 signaling, it is understood that EndMT can be flowmediated.54,55 This suggests a potential additional factor contributing to the occurrence of
EndMT in CLI. CLI is fundamentally caused by accumulation of atherosclerotic plaque in
the arteries that supply the lower leg.53 This results in a decrease in overall perfusion to
the distal vessels in the limb, inducing a low-flow environment. Endothelial cells are
responsive to flow rate and have been shown to undergo EndMT under both low-flow and
turbulent flow conditions, for example in atherosclerotic plaque found at artery branch
points.54,55 As CLI is understood to be a low-flow environment. I have considered if flow
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is a contributing factor to inducing partial EndMT in the arterioles of patients with CLI. To
better understand the implication of flow, an endothelial cell-specific flow model, such as
a microfluidics channel, should be employed to study endothelial cells under varying flow
rates, and with and without the addition of TGFb1 inhibitor, to better understand the
conditions under which EndMT is induced and results in the inward protrusion of
endothelial cells into the vessel lumen.

3.7

Conclusion
In conclusion, evaluation of the status of the microvasculature in patients with CLI

has brought about the discovery of non-atherosclerotic, non-thrombotic narrowing of
small arterioles. I further identified that the pathological restructuring of these distal
arterioles arises from partial endothelial to mesenchymal transition (EndMT).

The

findings uncover a previously unrecognized microvascular closure process that could
underlie the debilitating ischemic damage of critical limb ischemia.
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APPENDIX

Appendix A: Ethics Approval for Human Tissue

July 4, 2018
Use of Cadaveric Material – Ethics Approval Notice
Principal Investigator: Dr. Charles Rice
Review Number: 6-29-2018
Review level: Delegated
Approval Number specimens: 10 Fresh Cadavers
Protocol Title: Impacts of Chronic Inflammatory demyelinating polyneuropathy (CIDP) on the motor and
sensory nervous systems
Department & Institution: Western
Ethics Approval Date and Number: 07042018
Documents Reviewed and Approved & Documents Received for Information:

ACB Use of Cadaveric Material for Research Purposes Research Proposal Submission – Appendix I
Request for Photography/Videography – Appendix III
Version: 2
This is to notify that the University of Western Ontario Subcommittee for Cadaveric Material Research
Ethics has approved your request as indicated by the approval date and number listed above.
The ethics approval for this study shall remain valid for one year, at which time the PI must submit a study
completion form or contact the cadaveric material subcommittee Chair (or designate signed below) for an
extension or amendments.

___________________________________________
Signature

Schulich School of Medicine & Dentistry, Western University, Building, Rm. 491
1511 Richmond St. London, ON, Canada N6A 5C1
t. 519.661.2111 ext. 86756 www.schulich.uwo.ca
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Date: 27 June 2019
To: Dr. Douglas Hamilton
Project ID: 6311
Study Title: Role of periostin in the repair of skin - 16245E
Application Type: Continuing Ethics Review (CER) Form
Review Type: Delegated
REB Meeting Date: 02/Jul/2019
Date Approval Issued: 27/Jun/2019
REB Approval Expiry Date: 24/Jun/2020
Lapse in Approval: June 25, 2019 to June 27, 2019
____________________________________________________________________________
Dear Dr. Douglas Hamilton,
The Western University Research Ethics Board has reviewed the application. This study, including all currently approved documents, has been re-approved until the
expiry date noted above.
REB members involved in the research project do not participate in the review, discussion or decision.
Western University REB operates in compliance with, and is constituted in accordance with, the requirements of the TriCouncil Policy Statement: Ethical Conduct for
Research Involving Humans (TCPS 2); the International Conference on Harmonisation Good Clinical Practice Consolidated Guideline (ICH GCP); Part C, Division 5
of the Food and Drug Regulations; Part 4 of the Natural Health Products Regulations; Part 3 of the Medical Devices Regulations and the provisions of the Ontario
Personal Health Information Protection Act (PHIPA 2004) and its applicable regulations. The REB is registered with the U.S. Department of Health & Human Services
under the IRB registration number IRB 00000940.
Please do not hesitate to contact us if you have any questions.
Sincerely,
Daniel Wyzynski, Research Ethics Coordinator, on behalf of Dr. Joseph Gilbert, HSREB Chair
Note: This correspondence includes an electronic signature (validation and approval via an online system that is compliant with all regulations).
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Appendix B: Antibody Information

Target antigen
CD31 (a)

Vendor or Source
Thermo Fisher

Catalog #

Working
concentration

RB-10333-P1

1:50

Scientific
CD31 (b)

Agilent

M0823

1:20

SM-α-actin (a)

Agilent

M0851

1:100

SM-α-actin (b)

Novus

NB300-978

1:100

N-Cadherin

Novus

NB200-592

1:400

S100A4

Abcam

ab41532

1:100

Snail

Thermo Fisher

14-9859-82

1:50

Scientific
TGFb1

Abcam

ab92486

1:100

phospho-SMAD 2

Thermo Fisher

3108

1:100

sc-376381

1:100

715-005-151

1:100

115-005-166

1:100

111-065-144

1:100

SA-5649

1:200

Scientific
Endoglin

Santa Cruz
Biotechnology

biotinylated donkey

Jackson

anti-mouse IgG

ImmunoResearch

biotinylated goat

Jackson

anti-mouse IgG

ImmunoResearch

biotinylated goat

Jackson

anti-rabbit IgG

ImmunoResearch

DyLight 649-

Vector

conjugated

Laboratories

streptavidin
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Alexa Fluor 488-

Thermo Fisher

conjugated goat

Scientific

A11008

1:200

A11003

1:200

A11055

1:200

A10040

1:200

A31571

1:200

anti-rabbit IgG
Alexa Fluor 546-

Thermo Fisher

conjugated goat

Scientific

anti-mouse IgG
Alexa Fluor 488-

Thermo Fisher

conjugated donkey

Scientific

anti-goat IgG
Alexa Fluor 546-

Thermo Fisher

conjugated donkey

Scientific

anti-rabbit IgG
Alexa Fluor 647-

Thermo Fisher

conjugated donkey

Scientific

anti-mouse IgG
4’,6-diamidino-2phenylindole
(DAPI)
Fluoromount-G

SouthernBiotech

0100-020
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4.3

Appendix C: Co-Staining Information

Pair 1: CD31 and SM-α-actin
Primary Antibody
CD31 (a): Rabbit polyclonal

Secondary Antibody
Alexa Fluor 488- conjugated goat antirabbit IgG

SM-α-actin (a): Mouse monoclonal

Alexa Fluor 546-conjugated goat antimouse IgG

Pair 2: CD31 and N-cadherin
Primary Antibody

Secondary Antibody

CD31 (b): Mouse monoclonal anti-

biotinylated goat anti-mouse IgG

CD31

DyLight 649-conjugated streptavidin

N-Cadherin: Rabbit polyclonal

Alexa Fluor 488- conjugated goat antirabbit IgG

Pair 3: CD31 and S100A4
Primary Antibody

Secondary Antibody

CD31 (b): Mouse monoclonal anti-

biotinylated goat anti-mouse IgG

CD31

DyLight 649-conjugated streptavidin

S100A4: Rabbit polyclonal

Alexa Fluor 488- conjugated goat antirabbit IgG

Pair 4: CD31 and Snail1
Primary Antibody
CD31 (a): Rabbit polyclonal

Secondary Antibody
Alexa Fluor 488- conjugated goat antirabbit IgG

Snail1: Mouse monoclonal

biotinylated goat anti-mouse IgG
DyLight 649-conjugated streptavidin
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Pair 5: CD31 and pSMAD2
Primary Antibody

Secondary Antibody

CD31 (b): Mouse monoclonal anti-

biotinylated goat anti-mouse IgG

CD31

DyLight 649-conjugated streptavidin

pSmad2: Rabbit polyclonal

Alexa Fluor 488- conjugated goat antirabbit IgG

Triplet 1: CD31, SM-α-actin and TGFb1
Primary Antibody

Secondary Antibody

CD31 (b): Mouse monoclonal anti-

biotinylated goat anti-mouse IgG

CD31

DyLight 649-conjugated streptavidin

SM-α-actin (b): Goat polyclonal

Alexa Fluor 488-conjugated donkey antigoat IgG

TGFb1: Rabbit polyclonal

Alexa Fluor 546-conjugated donkey antirabbit IgG

Triplet 2: CD31, SM-α-actin and Endoglin
Primary Antibody
CD31 (a): Rabbit polyclonal

Secondary Antibody
Alexa Fluor 488- conjugated goat antirabbit IgG

SM-α-actin (b): Goat polyclonal

Alexa Fluor 488-conjugated donkey antigoat IgG

Endoglin: Mouse monoclonal

Alexa Fluor 647-conjugated donkey antimouse IgG
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4.4

Appendix D: Legends for Supplemental Video Files

Online Video 4.4.1: Normal arteriole immuostained for CD31 and DAPI counter stained
for nuclei (confocal 3-dimensional reconstruction, 4.5 µm z stack, 0.125 µm steps)

Online Video 4.4.2: Occluded arteriole immuostained for CD31 and DAPI counter
stained for nuclei (confocal 3-dimensional reconstruction, 4.5 µm z stack, 0.125 µm steps)

99
5

CURRICULUM VITAE

Jacqueline Chevalier
MSc Candidate
jcheval3@uwo.ca
Education
University of Western Ontario, M.Sc. Medical Biophysics [candidate]

[2017 – present]

Thesis: Microvascular Architecture and Vascular Cell Phenotypes
in Patients with Peripheral Artery Disease
Supervisor: Dr. J. G. Pickering

University of Windsor, B.Sc. – Honors [Major: Biochemistry]

[2012 – 16]

Publications
Balint, B., Yin, H., Nong, Z., Arpino, JM., O’Neil, C., Rogers, S. R., Randhawa, V. K., Fox, S. A., Chevalier, J.,
Lee, J.J. Chu, M. W.A., Pickering, J.G. Seno-destructive smooth muscle cells in the ascending aorta of
patients with bicuspid aortic valve disease. E.BioMedicine. (2019).

[In Preparation]
Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition.

Lee, J., Arpino, JM., Chevalier, J., Nong, Z., Szpakowski, A., Yin, H., Hashi, AA., O’Neil, C., Pickering, J.G.,
Angiogenesis in the Ischemic Mouse Hindlimb and the Translational Valley of Death

[Published Abstracts]
Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition. Arteriosclerosis, Thrombosis, and
Vascular Biology. (2019).

100
Lee, J., Arpino, JM., Nong, Z., Szpakowski, A., Yin, H., Hashi, AA., Chevalier, J., O’Neil, C., Pickering, J.G.,
Hindlimb Mapping and Systematic Review of Angiogenesis Following Mouse Hindlimb Ischemia: New
Insights Into Quality Assurance Imperatives. Arteriosclerosis, Thrombosis, and Vascular Biology. (2019).

Arpino, JM., Lee, J., Nong, Z., Szpakowski, A., Yin, H., Hashi, A.A., Chevalier, J., O’Neil, C., Pickering, J.G.
Unbiased Mapping of Mouse Ischemic Hindlimb Angiogenesis and Systematic Review: Quality Assurance
for Preclinical Angiogenesis Research. Journal of Atherosclerosis. (2018).

Presentations and Proceedings (Presenting Author)
Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition. Poster session presented at
Robarts Research Retreat, London, ON. (2019).

Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition. Vascular Discovery: From Genes to
Medicine 2019.

Lee, J., Arpino, JM., Nong, Z., Szpakowski, A., Yin, H., Hashi, AA., Chevalier, J., O’Neil, C., Pickering, J.G.,
Hindlimb Mapping and Systematic Review of Angiogenesis Following Mouse Hindlimb Ischemia: New
Insights Into Quality Assurance Imperatives. Vascular Discovery: From Genes to Medicine. (2019).

Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition. Vascular Research Initiatives
Conference (Society of Vascular Surgery). (2019).

Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Nong, Z., Prescott, E., Gilmore, K., Lee, J. J., Hewak, M., Rice,
C. L., Dubois, L., Power, A., Hamilton, D., Pickering, J.G. Microvascular Stenosis in End-Stage Peripheral
Artery Disease: Role of Partial Endothelial to Mesenchymal Transition. Poster session presented at London
Health Research Day, London, ON. (2019).

Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Lee, J., Dubois, L., Power, A., Hamilton, D., Pickering, J.G.,
Microvascular Architecture and Cell Phenotypes in Patients with Severe Peripheral Artery Disease. Poster
session presented at Robarts Research Retreat, London, ON. (2018).

101
Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Lee, J., Dubois, L., Power, A., Hamilton, D., Pickering, J.G.,
Microvascular Architecture and Cell Phenotypes in Patients with Severe Peripheral Artery Disease. Poster
session presented at London Health Research Day, London, ON. (2018).

Chevalier, J., Arpino, JM., Yin, H., O’Neil, C., Lee, J., Dubois, L., Power, A., Hamilton, D., Pickering, J.G.,
Microvascular Architecture and Cell Phenotypes in Patients with Severe Peripheral Artery Disease. Poster
session presented at Medical Residents Research Day, London, ON. (2018).

Chevalier, J. Under the Microscope: Understanding Peripheral Arterial Disease. 3MT University of Western
Top 20 Finalist. (2018).

Chevalier, J. Under the Microscope: Understanding Peripheral Arterial Disease. 3MT Schulich School of
Medicine and Dentistry (winner). (2018).

Work Experience
Chevalier Freelance:

[2012 – present]

Freelance performance horse grooming (clipping, braiding, mane pulling,
show grooming, bathing, mucking), dog and cat sitting, dog training
[References available upon request]

Talbot Animal Hospital:

[Jun 2018 – Jun 2019]

Assistant (surgical pack preparations, cleaning and facility maintenance,
pharmaceutical preparations, care for boarding animals, assisting with
procedures) and reception duties, (answering phones, billing, checking
patients in)

Robarts Research Institute:

[Jun - Sep 2017]

Summer Studentship: learning laboratory techniques including bright
field and fluorescence microscopy, confocal microscopy, tissue processing
and sectioning, immunohistochemistry, and histology techniques

Wingberry Farms:
Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,
turnout, muck stalls) and exercise horses (hunter/jumper), assist with
health care decisions and veterinarian procedures for performance horses,
clean and maintain facility and stable

[Apr – Jun 2017]

102
Karen Blum:

[Jan – Apr 2017]

Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,
turnout, muck stalls) and exercise horses (hunter/jumper), assist with
health care decisions and veterinarian procedures for performance horses,
clean and maintain facility and stable, care for family dogs

Tutor Doctor:

[Jan – Apr 2017]

Tutor: Tutoring high school level math and science. Determining the most
efficient method of teaching for each individual student, and designing
lesson plans that cater to their individual learning needs.

Beth Underhill Stables:

[Apr 2016 – Jan 2017]

Groom and Flat rider: Care for (grooming, clipping, bandaging, feed,
turnout, muck stalls) and exercise horses (hunter/jumper), assist with
veterinarian procedures for performance horses, clean and
maintain facility and stable

Ironstone Stables:

[2008 – Apr 16]

Coach and Staff: Care for, exercise and train horses (hunter/jumper),
equestrian coach, assist with health care decisions and veterinarian
procedures for performance horses, facility and stable maintenance
and cleaning, website maintenance and design

Volunteer Experience
Manning Equine Hospital:

[2018 – present]

Vaccinations, administering medications, pharmaceutical preparation
(injections, medication), sheath cleaning, scrubbing and clipping
for procedures

Windsor-Essex Therapeutic Riding Association:
Strides for Stability Chair: Planning and execution of the Strides for
Stability Fundraiser. Organizing and managing volunteers, obtaining
sponsorship, organizing and obtaining prizes, planning and running of
the two day horse show

[2015 – present]

103
Talbot Animal Hospital:

[2017 – Apr 2018]

Cleaning and facility maintenance, pharmaceutical preparations
(injections, medication) assisting with simple procedures
(IV line attachment and holding dog/cats/rabbits), active observer
of procedures (appointments, surgery, x-ray), surgical pack preparation

University of Windsor Equestrian Team:

[2014 – 16]

Treasurer: Organization and execution of the University of Windsor
horse show, planning and execution of fundraising events, maintaining
books and accounts for equestrian team

University of Windsor ‘Connecting4Success’:

[2014 – 16]

Mentor: Helping to guide first year students through the beginning of their
undergraduate degree by helping them locate resources provided
by the school, picking classes, encouraging professor-student rapport

University of Windsor ‘Walk Safe’:

[2014 – 16]

Escorting students safely through campus after hours

Dr. Jack Speirs:
Active observer in diagnostic imaging and interventional radiology,

[2015]

learning about various medical fields including cardiology, radiology,
neurology, and anesthesiology, learning aseptic principles

University of Windsor ‘Lead@UWindsor’

[2014 – 15]

Volunteering at student run and organized events on campus

Bally Bright Dairy Farm:

[summer 2013]

Dairy cow care (feed, handling, weaning), milking, cleaning, observation

Brack Animal Hospital:
Sweeping and cleaning, assisting with simple procedures
(IV line attachment and holding dog/cats/rabbits), observation,
assisting with grooming

[summer 2013]

104
Accomplishments, Awards and Scholarships
Poster award – Robarts Research Retreat (2019)
Poster award – Medical Residents Research Day (2018)
3 Minute Thesis University of Western – Top 20 Finalist (2018)
3 Minute Thesis Schulich School of Medicine and Dentistry – Finalist (2018)
Western Graduate Research Scholarship (2017)
‘Tutor of the Month’ Tutor Doctor (2017)
Nominated for Outstanding Youth in Philanthropy Award (2016)
University of Windsor Dean’s Honour Roll (2014 –16)
Canadian Interprovincial Equestrian Championships – Individual bronze medalist, team gold medalist (2013)
Ontario Outstanding Scholars Scholarship (Chemistry) (2012)
University of Windsor Entrance Scholarship (Chemistry) (2012)

